## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2020-09-23_Virtual Town Hall 27_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/142511/download?attachment
link youtube: https://youtu.be/gpU26VT95KA
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Virtual Town Hall: SARS-CoV-2 Testing Updates

QA Block 1-1
CLARIFIED QUESTION: What steps should developers take if a pre-EUA question is closed by the FDA with a reference to existing templates?
CLARIFIED ANSWER: Developers should refer to the FDA's validation recommendations in templates when pre-EUA questions are closed with template references. If the templates do not address their questions or a template does not exist, they should contact the FDA for further feedback.
VERBATIM QUESTION: What steps should developers take if a pre-EUA question is closed by the FDA with a reference to existing templates?
VERBATIM ANSWER: First of all, you know our templates contain important recommendations for validation and I encourage you to check those out. And then if folks, developers submit a pre-EUA and they ask questions that can be directly addressed by the templates, in order to assist us to most efficiently handle all of the applications that we get, we are going to typically close those by referencing the relevant templates. So we hope that works. If you have questions, you know that the templates don't go into them, that's where we'll focus most of our pre EUA response. And also, if there is something that you're asking that we haven't yet created a template or posted template, then obviously, that's important for us to see and provide feedback on. And again, the recommendations in the templates are exactly that, they are recommendations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA questions, FDA templates, Validation recommendations
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Under what circumstances should developers request feedback on alternative validation strategies?
CLARIFIED ANSWER: Developers should request feedback on alternative validation strategies to ensure alignment with FDA before conducting the work.
VERBATIM QUESTION: Under what circumstances should developers request feedback on alternative validation strategies?
VERBATIM ANSWER: We're are open to alternative validation strategies, we encourage you to check with us on those alternative strategies. So that we're all aligned prior to doing the work.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternative validation strategies, FDA alignment
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: For validation strategies not covered in existing templates, how should developers seek further guidance from the FDA?
CLARIFIED ANSWER: Developers should contact the FDA for feedback on validation strategies not covered in the existing templates, as the FDA focuses its pre-EUA responses on such questions.
VERBATIM QUESTION: For validation strategies not covered in existing templates, how should developers seek further guidance from the FDA?
VERBATIM ANSWER: If you have questions, you know that the templates don't go into them, that's where we'll focus most of our pre EUA response. And also, if there is something that you're asking that we haven't yet created a template or posted template, then obviously, that's important for us to see and provide feedback on.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation strategies, Pre-EUA guidance, Templates
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What are the expectations for kit manufacturers submitting pooling submissions to minimize lab bench work?
CLARIFIED ANSWER: FDA prioritizes pooling submissions where kit manufacturers enable labs to perform pooling with minimal or no bench work, enhancing efficiency.
VERBATIM QUESTION: What are the expectations for kit manufacturers submitting pooling submissions to minimize lab bench work?
VERBATIM ANSWER: There remains a robust interest in pooling and in particular kit manufacturers who have pooling submissions that would allow those kit users in the labs that use that kit to immediately pool with minimal work and perhaps no bench work for their own lab. That obviously greatly amplifies our efforts around trying to promote the opportunities for pooling.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling submissions, kit manufacturers, lab work reduction
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What criteria does the FDA use to prioritize the review of applications, particularly for pooling, point-of-care, and home testing?
CLARIFIED ANSWER: The FDA prioritizes applications for pooling, focusing on kits enabling immediate pooling with minimal work, as well as point-of-care and home tests, particularly molecular and antigen diagnostics, to expand testing.
VERBATIM QUESTION: What criteria does the FDA use to prioritize the review of applications, particularly for pooling, point-of-care, and home testing?
VERBATIM ANSWER: And then finally, I just wanted to go over some of the top priorities for review and for application processing. This is not an all-inclusive list. But does include some of them. There remains a robust interest in pooling and in particular kit manufacturers who have pooling submissions that would allow those kit users in the labs that use that kit to immediately pool with minimal work and perhaps no bench work for their own lab. That obviously greatly amplifies our efforts around trying to promote the opportunities for pooling. So those would be priority. And then point of care tests, especially those that are molecular in antigen remain high priorities. As to those that help us to expand testing further and that includes home collection, and home testing, especially for molecular diagnostics and antigen testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: application prioritization, pooling, home and point-of-care testing
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How should developers align their alternative validation approaches with the FDA before starting their work?
CLARIFIED ANSWER: FDA is open to alternative validation strategies and encourages developers to consult with them to ensure alignment before beginning work.
VERBATIM QUESTION: How should developers align their alternative validation approaches with the FDA before starting their work?
VERBATIM ANSWER: We're are open to alternative validation strategies, we encourage you to check with us on those alternative strategies. So that we're all aligned prior to doing the work.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternative validation strategies, developer-FDA alignment
REVIEW FLAG: False


#### 2. Pooling Validation Requirements for High, Moderate, and Point of Care

QA Block 2-1
CLARIFIED QUESTION: Can we secure the capability for pooling only for high and medium complexity contexts, but not for point of care?
CLARIFIED ANSWER: FDA allows pooling for high and medium complexity contexts without requiring point-of-care validation. However, for point-of-care pooling, the FDA would need usability data to ensure effective implementation by untrained personnel.
VERBATIM QUESTION: Can we secure the capability for pooling only for high and medium complexity contexts, but not for point of care?
VERBATIM ANSWER: So that's a great question, we can carve that out and specify in the instructions that's for some high end moderately complex lab situations, there are those that have expressed interest in pooling for point of care. It would, in addition to the typical analytical and clinical validation for pooling addition, we would also want to look at usability in the point of care setting. You're not asking that for now, I'm just providing a little bit of additional information for those potentially, on the call who are interested. But we, you know, we're open to pooling schemes at point of care. But again, we would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling for diagnostics, high and medium complexity, point of care settings
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Does the FDA have any hesitation in approving pooling for a product only for the CLIA context, but not at the point of care for that product?
CLARIFIED ANSWER: The FDA can approve pooling for specific contexts like high and moderate complexity labs, but point of care pooling requires additional usability validation to ensure untrained workers can perform it accurately.
VERBATIM QUESTION: Does the FDA have any hesitation in approving pooling for a product only for the CLIA context, but not at the point of care for that product?
VERBATIM ANSWER: So that's a great question, we can carve that out and specify in the instructions that's for some high end moderately complex lab situations, there are those that have expressed interest in pooling for point of care. It would, in addition to the typical analytical and clinical validation for pooling addition, we would also want to look at usability in the point of care setting. You're not asking that for now, I'm just providing a little bit of additional information for those potentially, on the call who are interested. But we, you know, we're open to pooling schemes at point of care. But again, we would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well. I hope that's helpful.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling approval, CLIA contexts, point of care testing
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: Does the FDA require blanket testing to demonstrate pooling acceptability in all three contexts: high complexity, moderate complexity, and waived status?
CLARIFIED ANSWER: The FDA does not require blanket testing for pooling across all contexts but specifies validation needs for each setting, such as additional usability data for point-of-care applications.
VERBATIM QUESTION: Does the FDA require blanket testing to demonstrate pooling acceptability in all three contexts: high complexity, moderate complexity, and waived status?
VERBATIM ANSWER: So that's a great question, we can carve that out and specify in the instructions that's for some high end moderately complex lab situations, there are those that have expressed interest in pooling for point of care. It would, in addition to the typical analytical and clinical validation for pooling addition, we would also want to look at usability in the point of care setting. You're not asking that for now, I'm just providing a little bit of additional information for those potentially, on the call who are interested. But we, you know, we're open to pooling schemes at point of care. But again, we would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pooling validation, CLIA vs point-of-care, Usability requirements
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: If we wanted to pursue point of care pooling, would human factors data be required to demonstrate healthcare workers can follow the pooling scheme?
CLARIFIED ANSWER: Human factors data would be required as part of a clinical study validation to ensure accurate results in point of care pooling, avoiding false negatives, false positives, and result mix-ups.
VERBATIM QUESTION: If we wanted to pursue point of care pooling, would human factors data be required to demonstrate healthcare workers can follow the pooling scheme?
VERBATIM ANSWER: Yes, in an actual clinical study validation to show they get accurate results doing pooling, that they don't get false negatives and false positives and they don't mix up results.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point of care pooling, human factors data, clinical study validation
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Are two separate studies required: a human factors study and a clinical study, or can a single clinical study examining user interaction suffice?
CLARIFIED ANSWER: The FDA stated that the human factors study and clinical study can be combined into one.
VERBATIM QUESTION: And are you requesting two separate city, the human factor study and a clinical study or just a clinical study that also examines user interaction?
VERBATIM ANSWER: I think they can be combined.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study requirements, human factors, clinical validation
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What usability requirements need to be satisfied for pooling in a point-of-care setting?
CLARIFIED ANSWER: The FDA requires that untrained healthcare workers in a point-of-care setting must demonstrate the ability to accurately perform pooling, including correctly convoluting and deconvoluting while achieving accurate results.
VERBATIM QUESTION: What usability requirements need to be satisfied for pooling in a point-of-care setting?
VERBATIM ANSWER: We would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care pooling, usability requirements, healthcare worker training
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What are the validation expectations to ensure healthcare workers at the point of care can accurately perform pooling without training?
CLARIFIED ANSWER: The FDA is open to pooling schemes at the point of care but requires validation showing untrained healthcare workers in such settings can accurately perform pooling, including convoluting and deconvoluting samples, while achieving accurate results.
VERBATIM QUESTION: What are the validation expectations to ensure healthcare workers at the point of care can accurately perform pooling without training?
VERBATIM ANSWER: We're open to pooling schemes at point of care. But again, we would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point of care pooling, validation requirements, healthcare worker performance
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: Is the FDA open to approving pooling schemes specifically tailored to point-of-care settings if additional usability criteria are met?
CLARIFIED ANSWER: The FDA is open to approving pooling schemes at point-of-care settings if usability criteria are met, including ensuring that untrained healthcare workers can execute pooling procedures accurately.
VERBATIM QUESTION: Is the FDA open to approving pooling schemes specifically tailored to point-of-care settings if additional usability criteria are met?
VERBATIM ANSWER: But we, you know, we're open to pooling schemes at point of care. But again, we would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling schemes, point-of-care diagnostics, FDA approval criteria
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: How does the FDA expect untrained healthcare workers to manage the pooling and deconvolution process to ensure result accuracy?
CLARIFIED ANSWER: The FDA is open to point-of-care pooling schemes but expects untrained healthcare workers to demonstrate the ability to accurately carry out pooling and deconvolution to ensure correct results.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: But we, you know, we're open to pooling schemes at point of care. But again, we would want to see that those untrained, you know, those health care workers in a point of care setting, who are not trained laboratorians can accurately carry out the pooling scheme and both convolute and deconvolute those and to get accurate results as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: point-of-care pooling, usability for untrained workers, diagnostic accuracy
REVIEW FLAG: False


#### 3. Diagnostic PCR Assay Review: Timing and Submission Factors

QA Block 3-1
CLARIFIED QUESTION: What has been the minimum average review time for authorization of a diagnostic PCR assay?
CLARIFIED ANSWER: The review time for diagnostic PCR assays varies based on priority, data quality, and adherence to FDA recommendations. High-priority tests may be reviewed quickly if issues are minimal, but delays occur when additional work or testing is needed.
VERBATIM QUESTION: Hi, this is Alyssa also, from User Wide. I have a question about what has been the minimum average review time for authorization of a diagnostic PCR assay?
VERBATIM ANSWER: That does vary considerably because of the notification pathway for these tests. We focus our attention on the highest priority items. Everyone within two weeks of an EUA submission should have a contact that they can communicate with. And those that are the highest priority and there's room on a reviewer's desk, can be moved into that slot. Once we move into interactive review with the reviewer. If there are no outstanding issues, the data is all there and the data looks good, And there's no additional testing that may be requested, Those applications move relatively quickly. However, if they're priority and they get into viewers desk, but there is a substantial amount of work yet to be done and additional testing and things like that it can slow things down. So, we do encourage developers to, as closely as possible, follow our recommendations and to pre check with us, you know, prior to doing any alternatives so that we don't lose time on either the developer side or on the reviewer's side. And also, you know if there are problems with the review, rather with the application, where there's clearly not a match between what our recommendations are and expectations are for performance and your actual test, That's going to slow things down as well. We do look at the ponderous of evidence, but by and large, we've set our recommendations, at what we believe are very appropriate levels. So, we are asking all developers to work with us and that will speed things up for all of us.
SPEAKER QUESTION: Alyssa Crustacea
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: review time for PCR assays, EUA submissions, developer compliance
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What steps can developers take to ensure their EUA submission prioritization?
CLARIFIED ANSWER: To ensure EUA submission prioritization, developers should follow FDA recommendations closely, communicate with FDA within two weeks of submission, and pre-check processes to avoid delays from additional testing or performance mismatches.
VERBATIM QUESTION: What steps can developers take to ensure their EUA submission prioritization?
VERBATIM ANSWER: We focus our attention on the highest priority items. Everyone within two weeks of an EUA submission should have a contact that they can communicate with. And those that are the highest priority and there's room on a reviewer's desk, can be moved into that slot. Once we move into interactive review with the reviewer. If there are no outstanding issues, the data is all there and the data looks good, And there's no additional testing that may be requested, Those applications move relatively quickly. However, if they're priority and they get into viewers desk, but there is a substantial amount of work yet to be done and additional testing and things like that it can slow things down. So, we do encourage developers to, as closely as possible, follow our recommendations and to pre check with us, you know, prior to doing any alternatives so that we don't lose time on either the developer side or on the reviewer's side. And also, you know if there are problems with the review, rather with the application, where there's clearly not a match between what our recommendations are and expectations are for performance and your actual test, That's going to slow things down as well. We do look at the ponderous of evidence, but by and large, we've set our recommendations, at what we believe are very appropriate levels.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, prioritization, developer guidance
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: How can developers pre-check with the FDA before pursuing alternative testing pathways?
CLARIFIED ANSWER: The FDA encourages developers to follow their recommendations and pre-check with them before pursuing alternative approaches to prevent delays for both developers and reviewers.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We do encourage developers to, as closely as possible, follow our recommendations and to pre check with us, you know, prior to doing any alternatives so that we don't lose time on either the developer side or on the reviewer's side.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-checking with FDA, testing pathway guidance, reducing delays in reviews
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What constitutes a mismatch between FDA recommendations and a developer's test performance expectations?
CLARIFIED ANSWER: A mismatch occurs when a test application does not align with FDA's performance recommendations, potentially delaying the review process.
VERBATIM QUESTION: What constitutes a mismatch between FDA recommendations and a developer's test performance expectations?
VERBATIM ANSWER: if there are problems with the review, rather with the application, where there's clearly not a match between what our recommendations are and expectations are for performance and your actual test, That's going to slow things down as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: application mismatch, performance expectations, FDA recommendations
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What happens if the data submitted with an EUA application is incomplete or insufficient?
CLARIFIED ANSWER: Incomplete or insufficient data may cause delays in the EUA process. FDA advises developers to follow recommendations closely and consult in advance to avoid potential issues.
VERBATIM QUESTION: What happens if the data submitted with an EUA application is incomplete or insufficient?
VERBATIM ANSWER: However, if they're priority and they get into viewers desk, but there is a substantial amount of work yet to be done and additional testing and things like that it can slow things down. So, we do encourage developers to, as closely as possible, follow our recommendations and to pre check with us, you know, prior to doing any alternatives so that we don't lose time on either the developer side or on the reviewer's side. And also, you know if there are problems with the review, rather with the application, where there's clearly not a match between what our recommendations are and expectations are for performance and your actual test, That's going to slow things down as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA application process, Incomplete or insufficient data, Application delays
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What are the FDA's expectations for the evidence supporting test performance?
CLARIFIED ANSWER: The FDA sets recommendations for test performance standards at what it considers appropriate levels, based on the totality of evidence.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We do look at the ponderous of evidence, but by and large, we've set our recommendations, at what we believe are very appropriate levels.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test performance standards, FDA recommendations
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: How can developers minimize delays during the interactive review process?
CLARIFIED ANSWER: Developers can minimize delays by closely following FDA's recommendations, pre-checking with the FDA before making alternatives, and ensuring their applications match FDA's performance recommendations.
VERBATIM QUESTION: How can developers minimize delays during the interactive review process?
VERBATIM ANSWER: We do encourage developers to, as closely as possible, follow our recommendations and to pre check with us, you know, prior to doing any alternatives so that we don't lose time on either the developer side or on the reviewer's side. And also, you know if there are problems with the review, rather with the application, where there's clearly not a match between what our recommendations are and expectations are for performance and your actual test, That's going to slow things down as well. We do look at the ponderous of evidence, but by and large, we've set our recommendations, at what we believe are very appropriate levels. So, we are asking all developers to work with us and that will speed things up for all of us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: minimizing delays, interactive review process, developer compliance
REVIEW FLAG: False


#### 4. FDA Submission Review Process and Timelines

QA Block 4-1
CLARIFIED QUESTION: If new studies not indicated in the pre-EUA are needed, does updating the submission result in losing the place in the review queue?
CLARIFIED ANSWER: FDA states that reviewers handle updates based on their discretion. They may pass the task to support staff for additional study design, and once the data returns, reviewers address it as soon as possible. To manage workload, reviewers continue with new applications in the meantime.
VERBATIM QUESTION: If new studies not indicated in the pre-EUA are needed, does updating the submission result in losing the place in the review queue?
VERBATIM ANSWER: So yes, that, you know, is mostly left up to the individual reviewer at this time. So, they don't waste time of theirs, they may hand that off to one of our other support staff, with the recommended additional study design. And then when that comes back in with that data, then that reviewer will be notified that the requested additional data has been provided. And then the reviewer as soon as they can, can get back to that. But in order to manage all the volume of applications as efficiently as possible, those reviewers will move on to new applications. So anyways, I wanted to provide that clarity to you.
SPEAKER QUESTION: Arvita Tripati
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA updates, submission process, review queue
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Is EUA review conducted on a rolling basis?
CLARIFIED ANSWER: EUA review is mostly managed at the discretion of individual reviewers and operates in a way that accommodates updates, but reviewers may move to new applications to manage volume.
VERBATIM QUESTION: Is EUA review conducted on a rolling basis?
VERBATIM ANSWER: So yes, that, you know, is mostly left up to the individual reviewer at this time. So, they don't waste time of theirs, they may hand that off to one of our other support staff, with the recommended additional study design. And then when that comes back in with that data, then that reviewer will be notified that the requested additional data has been provided. And then the reviewer as soon as they can, can get back to that. But in order to manage all the volume of applications as efficiently as possible, those reviewers will move on to new applications.
SPEAKER QUESTION: Arvita Tripati
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review process, Rolling review, Reviewer discretion
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: What is the current turnaround time for antigen testing review?
CLARIFIED ANSWER: Turnaround time for antigen testing review varies greatly based on the completeness, organization of data, and need for additional studies. While well-prepared applications may be reviewed quickly, high application volume and unclear submissions can cause delays.
VERBATIM QUESTION: What is the current turnaround time for antigen testing review?
VERBATIM ANSWER: So, again, it depends, it depends greatly on the application. When we receive an application that has everything there and it's well organized, easy to understand, the data are acceptable and no additional studies are needed. Those move incredibly fast. Obviously, we're having a lot more applications right now. Versus in the early days, when we can turn things around in as little as a day. Those times are not necessarily with us right now, because of the volume. And our desire to work with as many developers as our reviewers can handle in moving them along, all along as quickly as possible. So, it does vary greatly. So again, if additional studies are requested, that can slow things down, if things aren't clear. If study designs are not clear, we do look at more than the data, we look at the study designs to make sure that the studies were performed per our recommendations. And in that there are no potential factors that could influence our review. So, in addition to setting the data, it is great to have the study designs there. So, the fewer questions that we that we identify in the review, the fewer questions you the developers get to answer and the faster things go. So again, even for direct antigen, when those submissions are well put together, well organized, everything looks, you know, shipshape, then those can go incredibly fast.
SPEAKER QUESTION: Arvita Tripati
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen testing review, turnaround time, submission requirements
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: How are additional study recommendations communicated to developers when reviewers identify a need for them?
CLARIFIED ANSWER: FDA reviewers or support staff communicate the recommended additional study designs to developers. Once developers submit the data, the reviewer is notified and resumes review as soon as possible.
VERBATIM QUESTION: How are additional study recommendations communicated to developers when reviewers identify a need for them?
VERBATIM ANSWER: So yes, that, you know, is mostly left up to the individual reviewer at this time. So, they don't waste time of theirs, they may hand that off to one of our other support staff, with the recommended additional study design. And then when that comes back in with that data, then that reviewer will be notified that the requested additional data has been provided. And then the reviewer as soon as they can, can get back to that. But in order to manage all the volume of applications as efficiently as possible, those reviewers will move on to new applications.
SPEAKER QUESTION: Arvita Tripati
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: additional study recommendations, review process for submissions
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What happens to an application while a developer conducts additional studies requested by a reviewer?
CLARIFIED ANSWER: FDA reviewers may pass the application to support staff while additional studies are conducted. The original reviewer is notified upon receipt of the updated data, but they may have moved on to other applications in the meantime.
VERBATIM QUESTION: What happens to an application while a developer conducts additional studies requested by a reviewer?
VERBATIM ANSWER: So yes, that, you know, is mostly left up to the individual reviewer at this time. So, they don't waste time of theirs, they may hand that off to one of our other support staff, with the recommended additional study design. And then when that comes back in with that data, then that reviewer will be notified that the requested additional data has been provided. And then the reviewer as soon as they can, can get back to that. But in order to manage all the volume of applications as efficiently as possible, those reviewers will move on to new applications.
SPEAKER QUESTION: Arvita Tripati
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: application review process, additional studies, resource management
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: Does the FDA consider study design clarity as part of the application review process?
CLARIFIED ANSWER: FDA reviews study designs to ensure they follow recommendations and lack influential factors, evaluating more than just the data.
VERBATIM QUESTION: Does the FDA consider study design clarity as part of the application review process?
VERBATIM ANSWER: If study designs are not clear, we do look at more than the data, we look at the study designs to make sure that the studies were performed per our recommendations. And in that there are no potential factors that could influence our review. So, in addition to setting the data, it is great to have the study designs there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study designs, application review process
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: What factors in a study design might influence the FDA's review of a diagnostic application?
CLARIFIED ANSWER: FDA reviews study designs to ensure they follow recommendations, are clearly organized, and contain all necessary data to avoid delays. Poorly defined or unclear study designs can slow the review process.
VERBATIM QUESTION: What factors in a study design might influence the FDA's review of a diagnostic application?
VERBATIM ANSWER: So, again, it depends, it depends greatly on the application. When we receive an application that has everything there and it's well organized, easy to understand, the data are acceptable and no additional studies are needed. Those move incredibly fast. Obviously, we're having a lot more applications right now. Versus in the early days, when we can turn things around in as little as a day. Those times are not necessarily with us right now, because of the volume. And our desire to work with as many developers as our reviewers can handle in moving them along, all along as quickly as possible. So, it does vary greatly. So again, if additional studies are requested, that can slow things down, if things aren't clear. If study designs are not clear, we do look at more than the data, we look at the study designs to make sure that the studies were performed per our recommendations. And in that there are no potential factors that could influence our review. So, in addition to setting the data, it is great to have the study designs there. So, the fewer questions that we that we identify in the review, the fewer questions you the developers get to answer and the faster things go.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Study design clarity, Review process efficiency
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: How can applicants ensure their submissions are well-organized for faster review?
CLARIFIED ANSWER: To ensure faster review, applicants should provide complete, well-organized, and clear submissions, including acceptable study designs and data that meet FDA recommendations. Minimizing questions during review helps expedite the process.
VERBATIM QUESTION: How can applicants ensure their submissions are well-organized for faster review?
VERBATIM ANSWER: When we receive an application that has everything there and it's well organized, easy to understand, the data are acceptable and no additional studies are needed. Those move incredibly fast. Obviously, we're having a lot more applications right now. Versus in the early days, when we can turn things around in as little as a day. Those times are not necessarily with us right now, because of the volume. And our desire to work with as many developers as our reviewers can handle in moving them along, all along as quickly as possible. So, it does vary greatly. So again, if additional studies are requested, that can slow things down, if things aren't clear. If study designs are not clear, we do look at more than the data, we look at the study designs to make sure that the studies were performed per our recommendations. And in that there are no potential factors that could influence our review. So, in addition to setting the data, it is great to have the study designs there. So, the fewer questions that we that we identify in the review, the fewer questions you the developers get to answer and the faster things go. So again, even for direct antigen, when those submissions are well put together, well organized, everything looks, you know, shipshape, then those can go incredibly fast.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission organization, review process efficiency, recommendations for applicants
REVIEW FLAG: False


#### 5. Assessing Complexity for Point of Care Test Authorization

QA Block 5-1
CLARIFIED QUESTION: Could the substitution of a simpler liquid transfer mechanism take an assay from being a highly complex assay to a CLIA-waived point of care assay?
CLARIFIED ANSWER: The FDA evaluates whether untrained CLIA-waived lab workers can perform an assay with simplified tools like bulb pipettors instead of precision pipettes. Factors such as centrifugation, vortexing, or freezer requirements may influence the decision, assessed case-by-case, with flexibility during the pandemic.
VERBATIM QUESTION: Could the substitution of a simpler liquid transfer mechanism take an assay from being a highly complex assay to a CLIA-waived point of care assay?
VERBATIM ANSWER: First of all, precision pipetting with the calibrated pipette is not something that most CLIA waived labs have and nor are those healthcare workers trained in it's correct operation. However, most of the point of care devices, if they have a pipetting step, they have a little bulb, plastic bulb pipettor is common. You know, and so that's what we look for, things requiring centrifugation, things requiring vortexing, things requiring freezers, those are all you know, a little bit different. We will take them all one by one and assess them as to whether or not a CLIA waived environment worker can properly operate them. We are taking for at least this pandemic and in order to speed things along, we are maintaining a very open mind. That may, you know, as far as this, it may.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-waiver criteria, Assay complexity, Simpler liquid transfer
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: What are the fundamental components of an assay that FDA would deem appropriate for point of care authorization that is not linked to an existing platform?
CLARIFIED ANSWER: FDA requires that point-of-care assays be simple enough for untrained healthcare workers to use in CLIA-waived settings. The kit should be self-contained, have minimal steps, rely on easy-to-follow instructions (often pictorial), and not require laboratory equipment.
VERBATIM QUESTION: What are the fundamental components of an assay that FDA would deem appropriate for point of care authorization that is not linked to an existing platform?
VERBATIM ANSWER: The bottom line than an untrained user that is a healthcare worker in a CLIA Waived of setting, a clinic sort of setting. And now in this pandemic, it could be a school setting with a waiver, a certificate of waiver, or a work certificate of waiver and not anybody related at all to a health care facility in the prior, that they can open up the box, read the instructions perform the test accurately and get acceptable results. Bottom line, that's what it is. And they don't have, they don't have a laboratory setup. So, the more everything is self-contained within the kit, the better. The fewer the steps and reading the results and interpretation of the results should be straightforward. Typically, in that kind of CLIA waived of setting, you don't even have a long instructions for use. You have a quick user reference instructions, mostly pictures. Think of you know self-assembly of some, you know, home you know, furniture you might get from a store, from IKEA.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care assay requirements, FDA EUA process, CLIA-waived settings
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What are the common features of these newly authorized point of care devices in terms of complexity assessment?
CLARIFIED ANSWER: Point of care devices should be simple enough for healthcare workers in CLIA-waived settings to use without a lab setup. They must include self-contained kits, minimal steps, clear instructions, and straightforward result interpretation.
VERBATIM QUESTION: What are the common features of these newly authorized point of care devices in terms of complexity assessment?
VERBATIM ANSWER: The bottom line than an untrained user that is a healthcare worker in a CLIA Waived of setting, a clinic sort of setting. And now in this pandemic, it could be a school setting with a waiver, a certificate of waiver, or a work certificate of waiver and not anybody related at all to a health care facility in the prior, that they can open up the box, read the instructions perform the test accurately and get acceptable results. Bottom line, that's what it is. And they don't have, they don't have a laboratory setup. So, the more everything is self-contained within the kit, the better. The fewer the steps and reading the results and interpretation of the results should be straightforward. Typically, in that kind of CLIA waived of setting, you don't even have a long instructions for use. You have a quick user reference instructions, mostly pictures. Think of you know self-assembly of some, you know, home you know, furniture you might get from a store, from IKEA.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: POC device complexity, CLIA-waived environments, Instruction clarity
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: What are the general criteria for assessing test complexity outside of a pandemic?
CLARIFIED ANSWER: The FDA provides detailed information on its website about assessing test complexity outside of a pandemic. Although EUAs during the pandemic involve a slightly different threshold, the criteria for determining test simplicity and appropriateness for a CLIA-waived setting are still considered.
VERBATIM QUESTION: What are the general criteria for assessing test complexity outside of a pandemic?
VERBATIM ANSWER: And we do have quite a bit of information on our website about how we assess tests for complexity outside of pandemic. And while it's not, you know, completely the same situation because as Tim explained, these are not formally categorized during the EUA review they're just deemed waived for the purposes of the pandemic, we do consider the, you know, the information that we consider during a formal complexity review, we just may have a slightly different bar, you know, given the risk benefit analysis for the pandemic. But there is a lot of information about how we assess the simplicity of a test to determine whether it's appropriate for a CLIA waived setting.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Test complexity assessment, CLIA-waived settings, Pandemic vs. standard criteria
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What are the specific criteria for deeming a test as simple enough for CLIA-waived environments during the pandemic?
CLARIFIED ANSWER: FDA considers a test simple enough for CLIA-waived settings if untrained healthcare workers can perform it accurately with minimal steps and straightforward instructions, preferably using self-contained kits.
VERBATIM QUESTION: What are the specific criteria for deeming a test as simple enough for CLIA-waived environments during the pandemic?
VERBATIM ANSWER: The bottom line than an untrained user that is a healthcare worker in a CLIA Waived of setting, a clinic sort of setting. And now in this pandemic, it could be a school setting with a waiver, a certificate of waiver, or a work certificate of waiver and not anybody related at all to a health care facility in the prior, that they can open up the box, read the instructions perform the test accurately and get acceptable results. Bottom line, that's what it is. And they don't have, they don't have a laboratory setup. So, the more everything is self-contained within the kit, the better. The fewer the steps and reading the results and interpretation of the results should be straightforward. Typically, in that kind of CLIA waived of setting, you don't even have a long instructions for use. You have a quick user reference instructions, mostly pictures.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-waived test criteria, Simplification for untrained use, Pandemic adjustments
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: How does the FDA evaluate pipetting steps in determining test complexity for CLIA-waived point-of-care tests?
CLARIFIED ANSWER: The FDA evaluates test complexity by considering whether CLIA-waived labs and untrained healthcare workers can manage steps like pipetting. Precision pipetting is typically beyond their capabilities, but simpler tools like plastic bulb pipettors are considered feasible. Each test is reviewed individually.
VERBATIM QUESTION: How does the FDA evaluate pipetting steps in determining test complexity for CLIA-waived point-of-care tests?
VERBATIM ANSWER: Precision pipetting with the calibrated pipette is not something that most CLIA waived labs have and nor are those healthcare workers trained in it's correct operation. However, most of the point of care devices, if they have a pipetting step, they have a little bulb, plastic bulb pipettor is common. You know, and so that's what we look for, things requiring centrifugation, things requiring vortexing, things requiring freezers, those are all you know, a little bit different. We will take them all one by one and assess them as to whether or not a CLIA waived environment worker can properly operate them.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test complexity evaluation, CLIA-waived point-of-care tests, Pipetting steps
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What studies are recommended for point-of-care authorization of new antigen tests?
CLARIFIED ANSWER: For authorization of new antigen tests at point-of-care, the studies performed are outlined in the Instructions for Use (IFU) of authorized tests.
VERBATIM QUESTION: What studies are recommended for point-of-care authorization of new antigen tests?
VERBATIM ANSWER: Yes. So, you know, obviously, they then have done the point of care studies that we've recommended for that setting that was a direct antigen test. And so, you can look to that IFU to know the studies that they performed.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care test studies, Antigen test authorization
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: How does the FDA determine if workflows from previously authorized devices can be reused without additional studies?
CLARIFIED ANSWER: FDA does not require additional studies for previously authorized devices with identical workflows to speed up market access; volume and time parameters are the main considerations.
VERBATIM QUESTION: How does the FDA determine if workflows from previously authorized devices can be reused without additional studies?
VERBATIM ANSWER: So, for Abbott we've previously seen that device and authorized it for other targets such as the flu, I think. So, we don't ask them to do -- if the workflows, basically exactly the same, we don't ask them to do the guard band studies for this. I'm forgetting the exact terminology we use. But the study is around, you know, what are the volume parameters that are important to watch and the time parameters. So, workflows the same, we don't ask them to repeat that, that's just a way to speed things to market, but it's a new device.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA workflows, Device authorizations, FDA study requirements
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: What considerations under the emergency use authorization differ from normal CLIA complexity classifications?
CLARIFIED ANSWER: Under the EUA during the pandemic, FDA is more flexible and may allow considerations for waived status that would not apply outside of the pandemic. Waived status is temporary and not formally classified unless submitted for full approval.
VERBATIM QUESTION: What considerations under the emergency use authorization differ from normal CLIA complexity classifications?
VERBATIM ANSWER: We are taking for at least this pandemic and in order to speed things along, we are maintaining a very open mind. That may, you know, as far as this, it may. And I think we are being very flexible and allowing some things that outside of this pandemic situation, we might not. Again, the designation of waived status here is not - it's deemed, not actually formally classified. Formal classification for CLIA waiver would happen upon conversion to a full application at some subsequent point if that's what the developer does. So, these are in essence, temporary, deemed waived status.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA complexity classifications, Emergency Use Authorization, Pandemic-specific flexibility
REVIEW FLAG: False

QA Block 5-10
CLARIFIED QUESTION: What is the process for updating the molecular, antigen, and serology templates with new point-of-care studies during the pandemic?
CLARIFIED ANSWER: The molecular template currently includes point-of-care studies, while the antigen template does not but will be updated. Nine point-of-care tests are currently authorized, including five molecular and four antigen tests. Some of these represent new platforms developed during the pandemic.
VERBATIM QUESTION: What is the process for updating the molecular, antigen, and serology templates with new point-of-care studies during the pandemic?
VERBATIM ANSWER: And actually, we were both backwards on the template. So molecular template does have point of care, antigen does not but will be updated with it. For point of care tests, there are I believe, nine currently authorized. Five molecular and four antigen. And I think I want to say that there's about three molecular and two antigen, possibly, that are platforms that we have not previously seen before the pandemic.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Molecular template updates, Antigen template updates, Point-of-care test authorizations
REVIEW FLAG: False

QA Block 5-11
CLARIFIED QUESTION: What level of detail is required in the instructions for use for a CLIA-waived setting test?
CLARIFIED ANSWER: The instructions for CLIA-waived tests must enable an untrained user, such as a healthcare worker, to accurately perform the test in a non-laboratory setting. Instructions should be simple, preferably a quick reference guide with mostly pictures, and the test should be as self-contained and straightforward as possible.
VERBATIM QUESTION: What level of detail is required in the instructions for use for a CLIA-waived setting test?
VERBATIM ANSWER: The bottom line than an untrained user that is a healthcare worker in a CLIA Waived of setting, a clinic sort of setting. And now in this pandemic, it could be a school setting with a waiver, a certificate of waiver, or a work certificate of waiver and not anybody related at all to a health care facility in the prior, that they can open up the box, read the instructions perform the test accurately and get acceptable results. Bottom line, that's what it is. And they don't have, they don't have a laboratory setup. So, the more everything is self-contained within the kit, the better. The fewer the steps and reading the results and interpretation of the results should be straightforward. Typically, in that kind of CLIA waived of setting, you don't even have a long instructions for use. You have a quick user reference instructions, mostly pictures.
SPEAKER QUESTION: Daniel Marcus
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-waived settings, Instructions for use, Test complexity
REVIEW FLAG: False


#### 6. Evolving Role of Serology in Post-Vaccine Monitoring

QA Block 6-1
CLARIFIED QUESTION: What are your thoughts on the potential value of serology testing in a post-vaccine world, particularly for characterizing individual immune response and monitoring antibody response over time?
CLARIFIED ANSWER: The FDA acknowledges the value of serology testing in a post-vaccine world and remains committed to advancing it. However, addressing questions related to vaccines and antibody responses is complex and may require input from various FDA offices. The FDA encourages developers to initiate discussions on these topics.
VERBATIM QUESTION: What are your thoughts on the potential value of serology testing in a post-vaccine world, particularly for characterizing individual immune response and monitoring antibody response over time?
VERBATIM ANSWER: I think you're absolutely correct. And it's why, you know, we have a team dedicated to serology and advancing serology and will remain dedicated to that. When you move into a vaccine situation and you then start to potentially ask questions or try to answer questions relative to vaccines that does become a little bit more complex from a data perspective. And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing, Post-vaccine immune response, FDA collaboration
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: How might the demand for serology testing evolve in a post-vaccine world, potentially requiring millions to hundreds of millions of tests?
CLARIFIED ANSWER: The FDA anticipates potential growing complexity in serology testing post-vaccine. A dedicated team focuses on advancing serology, with future analyses possibly involving broader FDA collaboration. The FDA remains open to discussions in this area.
VERBATIM QUESTION: How might the demand for serology testing evolve in a post-vaccine world, potentially requiring millions to hundreds of millions of tests?
VERBATIM ANSWER: I think you're absolutely correct. And it's why, you know, we have a team dedicated to serology and advancing serology and will remain dedicated to that. When you move into a vaccine situation and you then start to potentially ask questions or try to answer questions relative to vaccines that does become a little bit more complex from a data perspective. And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing post-vaccine, FDA preparedness, Immune response monitoring
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Does data on antibody responses, including how they may vary by vaccine or ethnicity, affect the FDA's approach to evaluating serology tests?
CLARIFIED ANSWER: The FDA acknowledges the complexity of evaluating serology tests when considering factors like vaccine response and ethnicity. They will review such claims collaboratively with other FDA offices, emphasizing their openness to discussions.
VERBATIM QUESTION: Does data on antibody responses, including how they may vary by vaccine or ethnicity, affect the FDA's approach to evaluating serology tests?
VERBATIM ANSWER: I think you're absolutely correct. And it's why, you know, we have a team dedicated to serology and advancing serology and will remain dedicated to that. When you move into a vaccine situation and you then start to potentially ask questions or try to answer questions relative to vaccines that does become a little bit more complex from a data perspective. And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test evaluation, Antibody response data, FDA collaboration
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: Are there plans to address claims about whether immune responses to vaccines are adequate or not in the context of serology testing?
CLARIFIED ANSWER: FDA has a dedicated serology team and will evaluate requests related to vaccine immune response claims. Addressing such claims would involve multiple FDA offices.
VERBATIM QUESTION: Are there plans to address claims about whether immune responses to vaccines are adequate or not in the context of serology testing?
VERBATIM ANSWER: I think you're absolutely correct. And it's why, you know, we have a team dedicated to serology and advancing serology and will remain dedicated to that. When you move into a vaccine situation and you then start to potentially ask questions or try to answer questions relative to vaccines that does become a little bit more complex from a data perspective. And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology testing, vaccine immune responses, FDA evaluation
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Is the FDA open to starting discussions with developers about serology testing related to vaccine responses?
CLARIFIED ANSWER: The FDA has a dedicated serology team and is open to discussions with developers about serology testing related to vaccine responses.
VERBATIM QUESTION: Is the FDA open to starting discussions with developers about serology testing related to vaccine responses?
VERBATIM ANSWER: I think you're absolutely correct. And it's why, you know, we have a team dedicated to serology and advancing serology and will remain dedicated to that. When you move into a vaccine situation and you then start to potentially ask questions or try to answer questions relative to vaccines that does become a little bit more complex from a data perspective. And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing, Vaccine response, FDA collaboration
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: What criteria does the FDA use to rebalance resources between the molecular, antigen, and serology teams?
CLARIFIED ANSWER: The FDA has three separate teams dedicated to molecular, antigen, and serology, with resources shifted between teams as necessary to balance workload, while each team retains a core group of experts focused only on their specialty.
VERBATIM QUESTION: What criteria does the FDA use to rebalance resources between the molecular, antigen, and serology teams?
VERBATIM ANSWER: Yes, it's a great question and a little bit more transparency, and not that I didn't want to offer it before. But we have three teams, three separate teams, those who are expert at molecular, those who are expert at antigen and those that are expert at serology. And they are independent of one another and have their own priority of it. So, this serology team, you know, is 100% on serology. They're not they're not working on antigen; they're not working on molecular. They are 100% serology. And we do have the ability to shift resources from one team to another to balance the workload. And we have been actively rebalancing, when appropriate. But by and large, there's a core group in each of those areas who have a long history of working with developers for their specific technology, who are dedicated to those. So, serology for the serology team is all they're focused on and they're moving as quickly as they can.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Resource allocation, Molecular, antigen, and serology teams
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Does the FDA anticipate adjusting its resource allocation further in response to shifts in testing demand?
CLARIFIED ANSWER: The FDA has the capability to reallocate resources between teams to balance workloads and has been actively doing so as needed.
VERBATIM QUESTION: Does the FDA anticipate adjusting its resource allocation further in response to shifts in testing demand?
VERBATIM ANSWER: And we do have the ability to shift resources from one team to another to balance the workload. And we have been actively rebalancing, when appropriate.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: resource allocation, testing demand, team balancing
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: What is the process to seek FDA feedback on claims related to vaccine response adequacy?
CLARIFIED ANSWER: The FDA is open to reviewing claims regarding vaccine response adequacy, which may involve multiple FDA centers. Stakeholders are encouraged to initiate dialogues with the FDA.
VERBATIM QUESTION: What is the process to seek FDA feedback on claims related to vaccine response adequacy?
VERBATIM ANSWER: And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Vaccine response claims, FDA review process
REVIEW FLAG: False

QA Block 6-9
CLARIFIED QUESTION: When making claims about vaccine responses, what additional data or documentation would the FDA require from developers?
CLARIFIED ANSWER: The FDA acknowledges that making claims about vaccine responses involves complex data and may require collaboration across multiple FDA departments. Developers are encouraged to start dialogues with the FDA to discuss their ideas and data submissions.
VERBATIM QUESTION: When making claims about vaccine responses, what additional data or documentation would the FDA require from developers?
VERBATIM ANSWER: When you move into a vaccine situation and you then start to potentially ask questions or try to answer questions relative to vaccines that does become a little bit more complex from a data perspective. And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so. But again, you know, we remain open to ideas and open for business. So, if you want to start having those dialogues with us now, we're open to it.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaccine claims, FDA requirements, data complexity
REVIEW FLAG: False

QA Block 6-10
CLARIFIED QUESTION: Will discussions about serology testing and vaccine response claims involve multiple FDA offices or Centers beyond just the OIR?
CLARIFIED ANSWER: FDA confirms that discussing serology testing and vaccine response claims would involve other areas of the FDA beyond the OIR Office, as expected.
VERBATIM QUESTION: Will discussions about serology testing and vaccine response claims involve multiple FDA offices or Centers beyond just the OIR?
VERBATIM ANSWER: And you know, if you want to have some sort of claims around, you know, showing response say to a vaccine and whether that response is adequate or not, et cetera, et cetera. The agencies, you know, we'll take a look at those requests. I can't foretell exactly what our response would be. And it frankly, it would not involve just our Center and our, you know, our OIR Office, but likely other areas of the FDA, as you might expect, so.
SPEAKER QUESTION: Lin Hong
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology testing, vaccine response claims, FDA Centers involvement
REVIEW FLAG: False


#### 7. Developing Home Antigen Tests with FDA Guidance

QA Block 7-1
CLARIFIED QUESTION: Is it allowable to use a mid-turbinate swab instead of a nasopharyngeal swab for a home-use antigen test with FDA discussion?
CLARIFIED ANSWER: FDA is open to using mid-turbinate swabs for home-use antigen tests. However, considerations need to be made for children, such as adapting the swab for safety. Details on development and validation should be addressed with FDA's review staff or through the home test template email contact.
VERBATIM QUESTION: Is it allowable to use a mid-turbinate swab instead of a nasopharyngeal swab for a home-use antigen test with FDA discussion?
VERBATIM ANSWER: Okay. Well, we are very open to a home mid -turbinate use. And I don't know that we've authorized a mid-turbinate, but we've certainly expressed that in multiple occasions. The only caveat to that is in the home environment, we want to look at whether children would be swapped or not with a mid- turbinate. And if so, there are stoppers or other devices that can be utilized with a mid-turbinate swab that makes it appropriate for kids and it can be removed for adults. So that's the only sort of caveat on mid-turbinate. It would be unlikely for a direct antigen test to be more sensitive than a molecular test in the home situation. So, we want to compare it to an authorized version of the test, an EUA test, and typically I think in our recommendations, we say a high sensitivity test. And that can be performed in a lot of different settings. We're open to entirely in the true truly home setting. But you can also do have the users come into a simulated home environment and do testing. And then obviously, after they've collected the sample for your home test and tested it, they can be swapped by a healthcare worker and then sent in for an EUA authorized test. So probably some of those details that you're talking about, you know, would best be worked out with one of our review staff. So, if something is again, an alternate sort of pathway, then in our recommendations for the template from the home test template, then I would reach out through our templates email address and asked those specific targeted questions.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mid-turbinate swabs, home-use antigen tests, FDA guidelines
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Does the FDA require the use of only PCR tests that have been authorized for mid-turbinate sampling?
CLARIFIED ANSWER: The FDA does not require only PCR tests authorized for mid-turbinate sampling. The FDA is open to home mid-turbinate swab use under certain conditions, such as designing devices to safely swab children.
VERBATIM QUESTION: Does the FDA require the use of only PCR tests that have been authorized for mid-turbinate sampling?
VERBATIM ANSWER: Okay. Well, we are very open to a home mid -turbinate use. And I don't know that we've authorized a mid-turbinate, but we've certainly expressed that in multiple occasions. The only caveat to that is in the home environment, we want to look at whether children would be swapped or not with a mid- turbinate. And if so, there are stoppers or other devices that can be utilized with a mid-turbinate swab that makes it appropriate for kids and it can be removed for adults. So that's the only sort of caveat on mid-turbinate.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PCR test authorization, Mid-turbinate swab, Home test development
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Are mid-turbinate swabs appropriate for use in children for home tests, and are there specific requirements for their design?
CLARIFIED ANSWER: The FDA is open to the use of mid-turbinate swabs for home tests, but for children, stoppers or similar devices are required to ensure their suitability for kids, which can then be removed for adults.
VERBATIM QUESTION: Are mid-turbinate swabs appropriate for use in children for home tests, and are there specific requirements for their design?
VERBATIM ANSWER: Okay. Well, we are very open to a home mid -turbinate use. And I don't know that we've authorized a mid-turbinate, but we've certainly expressed that in multiple occasions. The only caveat to that is in the home environment, we want to look at whether children would be swapped or not with a mid- turbinate. And if so, there are stoppers or other devices that can be utilized with a mid-turbinate swab that makes it appropriate for kids and it can be removed for adults.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mid-turbinate swabs, home tests, pediatric use
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Is it acceptable to compare a home antigen test to an EUA-authorized high sensitivity molecular test during validation?
CLARIFIED ANSWER: The FDA recommends comparing a home antigen test to an EUA-authorized high sensitivity molecular test. Validation can occur in various settings, including simulated or actual home environments.
VERBATIM QUESTION: Is it acceptable to compare a home antigen test to an EUA-authorized high sensitivity molecular test during validation?
VERBATIM ANSWER: It would be unlikely for a direct antigen test to be more sensitive than a molecular test in the home situation. So, we want to compare it to an authorized version of the test, an EUA test, and typically I think in our recommendations, we say a high sensitivity test. And that can be performed in a lot of different settings. We're open to entirely in the true truly home setting. But you can also do have the users come into a simulated home environment and do testing. And then obviously, after they've collected the sample for your home test and tested it, they can be swapped by a healthcare worker and then sent in for an EUA authorized test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of home antigen tests, Comparison to EUA-authorized molecular tests, Home and simulated environments
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: Can validation of a home antigen test be conducted in a simulated home environment instead of an actual home?
CLARIFIED ANSWER: Validation for a home antigen test can be done in a simulated home environment or a true home setting, provided samples are compared with an EUA-authorized test.
VERBATIM QUESTION: Can validation of a home antigen test be conducted in a simulated home environment instead of an actual home?
VERBATIM ANSWER: We are very open to a home mid-turbinate use. And I don't know that we've authorized a mid-turbinate, but we've certainly expressed that in multiple occasions. The only caveat to that is in the home environment, we want to look at whether children would be swapped or not with a mid- turbinate. And if so, there are stoppers or other devices that can be utilized with a mid-turbinate swab that makes it appropriate for kids and it can be removed for adults. So that's the only sort of caveat on mid-turbinate. It would be unlikely for a direct antigen test to be more sensitive than a molecular test in the home situation. So, we want to compare it to an authorized version of the test, an EUA test, and typically I think in our recommendations, we say a high sensitivity test. And that can be performed in a lot of different settings. We're open to entirely in the true truly home setting. But you can also do have the users come into a simulated home environment and do testing. And then obviously, after they've collected the sample for your home test and tested it, they can be swapped by a healthcare worker and then sent in for an EUA authorized test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home antigen test validation, Simulated home environment testing
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: What are the steps to follow in the validation process when using a healthcare worker to collect a follow-up sample after a home test?
CLARIFIED ANSWER: Users can collect the sample for the home test in a simulated home environment. After testing it, a healthcare worker can collect a follow-up sample to be sent for an EUA authorized test.
VERBATIM QUESTION: What are the steps to follow in the validation process when using a healthcare worker to collect a follow-up sample after a home test?
VERBATIM ANSWER: But you can also do have the users come into a simulated home environment and do testing. And then obviously, after they've collected the sample for your home test and tested it, they can be swapped by a healthcare worker and then sent in for an EUA authorized test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation process, Follow-up sampling, EUA test requirements
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: Is there a specific process for reaching out to FDA review staff to address alternate pathways not covered in the home test template guidelines?
CLARIFIED ANSWER: FDA recommends reaching out through their templates email address for specific targeted questions about alternate pathways not covered in the home test template guidelines.
VERBATIM QUESTION: Is there a specific process for reaching out to FDA review staff to address alternate pathways not covered in the home test template guidelines?
VERBATIM ANSWER: So probably some of those details that you're talking about, you know, would best be worked out with one of our review staff. So, if something is again, an alternate sort of pathway, then in our recommendations for the template from the home test template, then I would reach out through our templates email address and asked those specific targeted questions.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternate pathways, FDA review staff, home test template guidelines
REVIEW FLAG: False


#### 8. WHO and CDC Standards Alignment for SARS-CoV-2 Tests

QA Block 8-1
CLARIFIED QUESTION: Will the FDA have a preference between the CDC standards and the WHO standards for quantitative antibody assays?
CLARIFIED ANSWER: The FDA does not currently have an answer regarding a preference between CDC and WHO standards, but is open to considering any international standards and is actively working with WHO.
VERBATIM QUESTION: Will the FDA have a preference between the CDC standards and the WHO standards for quantitative antibody assays?
VERBATIM ANSWER: You know, that's a question I don't know the answer to right off the top of my head. We are open to any - to considering any international standard. We're obviously working with the WHO. Toby, are you aware specifically is the CDC doing something separate? Because I know that in all likelihood there are multiple parties within us government involved in the WHO standard development, not just for serology, but for antigen and molecular tests as well.
SPEAKER QUESTION: Elliot Cowan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC vs WHO standards, Quantitative antibody assays
REVIEW FLAG: True

QA Block 8-3
CLARIFIED QUESTION: Is the CDC doing something separate from WHO in standard development for quantitative antibody assays?
CLARIFIED ANSWER: FDA is not aware of whether CDC is developing standards separate from WHO but recommends reaching out to CDC for clarity.
VERBATIM QUESTION: Is the CDC doing something separate from WHO in standard development for quantitative antibody assays?
VERBATIM ANSWER: No, I'm not aware, that's probably a question better for the for CDC. And I think generally we would, you know, be involved as much as possible and evaluate whatever standards are, are put out prior to commenting on them.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Standards for antibody assays, CDC and WHO roles
REVIEW FLAG: False


#### 9. Delayed Reviewer Assignment for EUA Submission Process

QA Block 9-1
CLARIFIED QUESTION: Who should be contacted to request a reviewer be assigned for an EUA submission when no updates have been received for months?
CLARIFIED ANSWER: If no updates on an EUA submission have been received for months, email cdrh-eua-templates@fda.hhs.gov and request Dr. Stenzel or Toby Lowe to address the issue.
VERBATIM QUESTION: Who should be contacted to request a reviewer be assigned for an EUA submission when no updates have been received for months?
VERBATIM ANSWER: So hopefully, you have some sort of contact in our office so that you can ask questions and we get updates on a weekly basis, that is my direction. But in this particular case, because it's been so long, I would like to understand a little bit more detail. So, if you send an email to our cdrh-eua- templates@fda.hhs.gov email, the common email address for this pandemic for covid related tests and ask for Doctor Stenzel or Toby Lowe and we will look into details and either communicate directly with you or have someone else get back to you.
SPEAKER QUESTION: Ian McLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, reviewer assignment, contact email
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: What is the expected timeline for assigning a new reviewer after an error in initial assignment?
CLARIFIED ANSWER: Contact the FDA at their provided email address, provide details, and either Doctor Stenzel or another representative will look into the matter and respond directly or through someone else.
VERBATIM QUESTION: What is the expected timeline for assigning a new reviewer after an error in initial assignment?
VERBATIM ANSWER: So hopefully, you have some sort of contact in our office so that you can ask questions and we get updates on a weekly basis, that is my direction. But in this particular case, because it's been so long, I would like to understand a little bit more detail. So, if you send an email to our cdrh-eua- templates@fda.hhs.gov email, the common email address for this pandemic for covid related tests and ask for Doctor Stenzel or Toby Lowe and we will look into details and either communicate directly with you or have someone else get back to you.
SPEAKER QUESTION: Ian McLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Reviewer assignment process, Contacting FDA
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: How frequently does the FDA recommend developers should expect updates on their submissions?
CLARIFIED ANSWER: The FDA recommends developers should receive updates on a weekly basis.
VERBATIM QUESTION: How frequently does the FDA recommend developers should expect updates on their submissions?
VERBATIM ANSWER: So hopefully, you have some sort of contact in our office so that you can ask questions and we get updates on a weekly basis, that is my direction.
SPEAKER QUESTION: Ian McLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission updates, FDA guidance
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Who should developers contact if there is uncertainty or prolonged delays in the EUA review process?
CLARIFIED ANSWER: Developers should email cdrh-eua-templates@fda.hhs.gov and address it to either Doctor Stenzel or Toby Lowe for detailed assistance in case of prolonged delays in the EUA review process.
VERBATIM QUESTION: Who should developers contact if there is uncertainty or prolonged delays in the EUA review process?
VERBATIM ANSWER: So hopefully, you have some sort of contact in our office so that you can ask questions and we get updates on a weekly basis, that is my direction. But in this particular case, because it's been so long, I would like to understand a little bit more detail. So, if you send an email to our cdrh-eua- templates@fda.hhs.gov email, the common email address for this pandemic for covid related tests and ask for Doctor Stenzel or Toby Lowe and we will look into details and either communicate directly with you or have someone else get back to you.
SPEAKER QUESTION: Ian McLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review delays, Contacting FDA, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Can developers escalate their issues directly to Dr. Stenzel or Toby Lowe in case of prolonged delays?
CLARIFIED ANSWER: Developers experiencing prolonged delays can contact the FDA office via the cdrh-eua-templates@fda.hhs.gov email, requesting attention from Dr. Stenzel or Toby Lowe, to ensure follow-up and resolution.
VERBATIM QUESTION: Can developers escalate their issues directly to Dr. Stenzel or Toby Lowe in case of prolonged delays?
VERBATIM ANSWER: So hopefully, you have some sort of contact in our office so that you can ask questions and we get updates on a weekly basis, that is my direction. But in this particular case, because it's been so long, I would like to understand a little bit more detail. So, if you send an email to our cdrh-eua- templates@fda.hhs.gov email, the common email address for this pandemic for covid related tests and ask for Doctor Stenzel or Toby Lowe and we will look into details and either communicate directly with you or have someone else get back to you.
SPEAKER QUESTION: Ian McLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA reviewer assignment, Escalation process, Contact methods
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Is there a specific protocol for addressing errors in reviewer assignment during the EUA process?
CLARIFIED ANSWER: The FDA recommends contacting their office through the cdrh-eua-templates@fda.hhs.gov email, addressing either Dr. Stenzel or Toby Lowe, to resolve reviewer assignment issues and receive updates.
VERBATIM QUESTION: Is there a specific protocol for addressing errors in reviewer assignment during the EUA process?
VERBATIM ANSWER: So hopefully, you have some sort of contact in our office so that you can ask questions and we get updates on a weekly basis, that is my direction. But in this particular case, because it's been so long, I would like to understand a little bit more detail. So, if you send an email to our cdrh-eua- templates@fda.hhs.gov email, the common email address for this pandemic for covid related tests and ask for Doctor Stenzel or Toby Lowe and we will look into details and either communicate directly with you or have someone else get back to you.
SPEAKER QUESTION: Ian McLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Reviewer assignment errors, EUA process communication
REVIEW FLAG: False


#### 10. Benchmarks for Sensitivity and Detection in High Complexity Testing

QA Block 10-1
CLARIFIED QUESTION: What is the benchmark for sensitivity and specificity for a LAMP assay being validated using the CDC PCR as a reference test?
CLARIFIED ANSWER: The FDA recommends that viral detection tests not fall below 80% positive percent agreement (PPA), and ideally achieve 95% or more sensitivity compared to an EUA-authorized molecular test. If sensitivity is below 95%, authorizations may include limitations such as presuming negatives as negative.
VERBATIM QUESTION: What is the benchmark for sensitivity and specificity for a LAMP assay being validated using the CDC PCR as a reference test?
VERBATIM ANSWER: Hi, yes, no, that's fine. You know, we've really recommend that no that no viral detection test, single use, you know, whether it's antigen or molecular fall below an 80% percent positive agreement of PPA or in other you know kind of another term for sensitivity. You know, we ideally would like to see, you know, a sensitivity of greater than 95% greater than or equal to 95% in comparison to an EUA authorized by sensitivity molecular test. But we can authorize, if it falls below that 95. There may be some limitations in the language such as negatives may be presumed negative, rather than negatives. So, we are open to new technology that fall below that standard molecular comparison target, even in the high complexity labs.
SPEAKER QUESTION: UnknownSpeaker 1
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Benchmark sensitivity/specificity, LAMP assays, FDA molecular diagnostic standards
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Do you have a marker for the limit of detection, such as 100 or 1000 virus copies?
CLARIFIED ANSWER: Developers conduct their own limit of detection (LOD) studies, and methods may vary. FDA recommends using live or inactivated virus and offers a reference panel for determining relative LOD, which developers can request.
VERBATIM QUESTION: Do you have a marker for the limit of detection, such as 100 or 1000 virus copies?
VERBATIM ANSWER: So, you know, each developer performs limited detection studies so that, in in their authorized test, users can see not only how they did it, but what the termination is. And, and those methods can vary greatly and have been very varied throughout this pandemic. Early on when samples or all virus was not even available. Now, we do recommend that live or inactivated virus be used for those LOD studies. And then, we also now have the FDA reference panel. So, developers who have a locked down device and would like to initiate the testing of their device using our relative LOD FDA reference panel can request that panel and on a case by case basis for those who haven't yet submitted even in EUA, we will look at that those who have submitted an EUA can request that now as well. And obviously, those who have an EUA authorization, we have been contacting all EUA authorized test developers asking for shipping information and then sending them the panel and working with them. And working on determining with that panel, what we can say about the relative LOD using the FDA panel and then obviously working to post those results which we already have. So long winded answers saying a lot of different things taking pause there if you want any clarification.
SPEAKER QUESTION: Sherry
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Limit of Detection (LOD), FDA reference panel, Diagnostic assay validation
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What is the FDA's minimum positive percent agreement (PPA) requirement for viral detection tests, including both antigen and molecular tests?
CLARIFIED ANSWER: The FDA recommends a minimum PPA of 80% for viral detection tests, with an ideal sensitivity of 95% or greater compared to an EUA-authorized molecular test. Tests with less than 95% sensitivity may have limitations in their authorization language.
VERBATIM QUESTION: What is the FDA's minimum positive percent agreement (PPA) requirement for viral detection tests, including both antigen and molecular tests?
VERBATIM ANSWER: We've really recommend that no that no viral detection test, single use, you know, whether it's antigen or molecular fall below an 80% percent positive agreement of PPA or in other you know kind of another term for sensitivity. You know, we ideally would like to see, you know, a sensitivity of greater than 95% greater than or equal to 95% in comparison to an EUA authorized by sensitivity molecular test. But we can authorize, if it falls below that 95. There may be some limitations in the language such as negatives may be presumed negative, rather than negatives. So, we are open to new technology that fall below that standard molecular comparison target, even in the high complexity labs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Positive Percent Agreement (PPA), Sensitivity benchmarks for tests, FDA authorization policies
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Can viral detection tests with sensitivity below 95% still receive authorization if specific language or limitations are included in the labeling?
CLARIFIED ANSWER: The FDA prefers viral detection tests to have a sensitivity of 95% or greater; however, tests with lower sensitivity can still receive authorization with specific limitations in labeling, such as indicating that negatives are presumed negative.
VERBATIM QUESTION: Can viral detection tests with sensitivity below 95% still receive authorization if specific language or limitations are included in the labeling?
VERBATIM ANSWER: You know, we ideally would like to see, you know, a sensitivity of greater than 95% greater than or equal to 95% in comparison to an EUA authorized by sensitivity molecular test. But we can authorize, if it falls below that 95. There may be some limitations in the language such as negatives may be presumed negative, rather than negatives. So, we are open to new technology that fall below that standard molecular comparison target, even in the high complexity labs.
SPEAKER QUESTION: UnknownSpeaker 1
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity of viral detection tests, EUA authorization criteria, Labeling requirements
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Does the FDA require live or inactivated virus for limit of detection (LOD) studies?
CLARIFIED ANSWER: The FDA recommends using live or inactivated virus for limit of detection (LOD) studies and also offers an FDA reference panel for developers to assess relative LOD.
VERBATIM QUESTION: Does the FDA require live or inactivated virus for limit of detection (LOD) studies?
VERBATIM ANSWER: Now, we do recommend that live or inactivated virus be used for those LOD studies. And then, we also now have the FDA reference panel. So, developers who have a locked down device and would like to initiate the testing of their device using our relative LOD FDA reference panel can request that panel and on a case by case basis for those who haven't yet submitted even in EUA, we will look at that those who have submitted an EUA can request that now as well. And obviously, those who have an EUA authorization, we have been contacting all EUA authorized test developers asking for shipping information and then sending them the panel and working with them. And working on determining with that panel, what we can say about the relative LOD using the FDA panel and then obviously working to post those results which we already have.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LOD studies, Live or inactivated virus, FDA reference panel
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What is the process for requesting the FDA reference panel for a locked-down device?
CLARIFIED ANSWER: Locked-down device developers can request the FDA reference panel, whether or not they have submitted for EUA. EUA-authorized developers are contacted directly to provide shipping information for the panel.
VERBATIM QUESTION: What is the process for requesting the FDA reference panel for a locked-down device?
VERBATIM ANSWER: So, developers who have a locked down device and would like to initiate the testing of their device using our relative LOD FDA reference panel can request that panel and on a case by case basis for those who haven't yet submitted even in EUA, we will look at that those who have submitted an EUA can request that now as well. And obviously, those who have an EUA authorization, we have been contacting all EUA authorized test developers asking for shipping information and then sending them the panel and working with them. And working on determining with that panel, what we can say about the relative LOD using the FDA panel and then obviously working to post those results which we already have.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA reference panel, Locked-down device testing process, EUA submissions
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: Can developers request the FDA reference panel even if they have not yet submitted an Emergency Use Authorization (EUA) application?
CLARIFIED ANSWER: Developers with a finalized device may request the FDA reference panel even without having submitted an EUA application, as requests are assessed on a case-by-case basis.
VERBATIM QUESTION: Can developers request the FDA reference panel even if they have not yet submitted an Emergency Use Authorization (EUA) application?
VERBATIM ANSWER: So, developers who have a locked down device and would like to initiate the testing of their device using our relative LOD FDA reference panel can request that panel and on a case by case basis for those who haven't yet submitted even in EUA, we will look at that those who have submitted an EUA can request that now as well. And obviously, those who have an EUA authorization, we have been contacting all EUA authorized test developers asking for shipping information and then sending them the panel and working with them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA reference panel, EUA application, Device testing
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: How does the FDA determine and post relative LOD results using the FDA reference panel?
CLARIFIED ANSWER: FDA uses the reference panel to evaluate relative LOD, which developers can request for authorized or submitted EUA tests. Results are then analyzed and posted.
VERBATIM QUESTION: How does the FDA determine and post relative LOD results using the FDA reference panel?
VERBATIM ANSWER: So, you know, each developer performs limited detection studies so that, in in their authorized test, users can see not only how they did it, but what the termination is. And, and those methods can vary greatly and have been very varied throughout this pandemic. Early on when samples or all virus was not even available. Now, we do recommend that live or inactivated virus be used for those LOD studies. And then, we also now have the FDA reference panel. So, developers who have a locked down device and would like to initiate the testing of their device using our relative LOD FDA reference panel can request that panel and on a case by case basis for those who haven't yet submitted even in EUA, we will look at that those who have submitted an EUA can request that now as well. And obviously, those who have an EUA authorization, we have been contacting all EUA authorized test developers asking for shipping information and then sending them the panel and working with them. And working on determining with that panel, what we can say about the relative LOD using the FDA panel and then obviously working to post those results which we already have.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA reference panel, Relative LOD, EUA test processes
REVIEW FLAG: False


#### 11. Guidelines for At-Home Antigen Test Performance and Usability Studies

QA Block 11-1
CLARIFIED QUESTION: What are the differences in positive predictive value between home use diagnostic kits and home use surveillance kits in a multipack format?
CLARIFIED ANSWER: The FDA defines surveillance as population-level observation without individual CLIA results. They recommend using EUA-authorized tests, but it's not required. For home diagnostic kits (symptomatic individuals) and home screening kits (asymptomatic but at risk), FDA templates provide clear performance expectations. They distinguish between positive predictive value (PPV), which is population-based, and positive percent agreement (PPA), which measures accuracy against a reference test. PPV for antigen tests can vary widely depending on population infection rates.
VERBATIM QUESTION: What are the differences in positive predictive value between home use diagnostic kits and home use surveillance kits in a multipack format?
VERBATIM ANSWER: So, for truly surveillance purposes as defined in our FAQ, and you can go there, for this pandemic, the FDA is not reviewing those. We do obviously recommend that in those situations an EUA authorized test be used, but it's not a requirement. And there are different, you can check with CMS and in CLIA, there are different reporting, you know, there I don't believe there's reporting requirements, but double check with them. So, for home use diagnosis, that's somebody with symptoms, home use screening, for those who may otherwise be at risk and could be asymptomatic carriers. There are clear recommendations in our templates, if you go to our template at the FDA website for what's probably called home use testing includes both molecular and antigen recommendations for that environment, it has all the recommended performance expectation. When you're talking about PPV, there's difference between PPV and PPA positive predictive value versus percent positive agreement. Percent positive agreement is when you're comparing your method to some other method. We recommend EUA authorized high sensitivity molecular test. That's really looking at you know, when the reference test is positive, how many times out of 100 is your test that you're developing positive? So, if it's positive, say, you know 90% of the time when the high sensitivity molecular test is positive, then your PPA or sensitivity would be 90%. Positive predictive value has to do with it's more of a population based measure. Yes, we do look at PPV for direct antigen tests, but that PPV can vary widely depending on the percent positivity in a given population.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Positive predictive value (PPV), Home use diagnostic and surveillance kits, FDA recommendations
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Does surveillance mean something specific in this context, as distinct from screening and home use diagnosis?
CLARIFIED ANSWER: Surveillance is defined by the FDA as assessing the presence or level of a virus in a population without providing CLIA results.
VERBATIM QUESTION: Does surveillance mean something specific in this context, as distinct from screening and home use diagnosis?
VERBATIM ANSWER: I understood home use diagnosis and then I'm not sure if you meant screening when you saying surveillance or are you talking truly surveillance as we have defined on our FDA FAQ webpage. Surveillance being that you're not really providing a CLIA result. You're doing population assessment of the presence or absence and at what level of the virus in it, in a targeted population basis.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: surveillance definition, screening vs surveillance, diagnostic tests
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: What are the FDA's recommendations for positive predictive value for individual tests and for overall multipack tests in the context of at-home use screening and diagnosis?
CLARIFIED ANSWER: The FDA looks at positive predictive value (PPV) for direct antigen tests, acknowledging that PPV depends on population positivity rates. However, there is no specific PPV recommendation. For home tests, FDA outlines expectations for specificity, sensitivity, and performance in templates. For single-use tests, 80% sensitivity is preferred, but lower sensitivity (70%) may be acceptable for serial tests achieving combined performance above 80%.
VERBATIM QUESTION: What are the FDA's recommendations for positive predictive value for individual tests and for overall multipack tests in the context of at-home use screening and diagnosis?
VERBATIM ANSWER: All right, so, yes. So, for truly surveillance purposes as defined in our FAQ, and you can go there, for this pandemic, the FDA is not reviewing those. We do obviously recommend that in those situations an EUA authorized test be used, but it's not a requirement. And there are different, you can check with CMS and in CLIA, there are different reporting, you know, there I don't believe there's reporting requirements, but double check with them. So, for home use diagnosis, that's somebody with symptoms, home use screening, for those who may otherwise be at risk and could be asymptomatic carriers. There are clear recommendations in our templates, if you go to our template at the FDA website for what's probably called home use testing includes both molecular and antigen recommendations for that environment, it has all the recommended performance expectation. When you're talking about PPV, there's difference between PPV and PPA positive predictive value versus percent positive agreement. Percent positive agreement is when you're comparing your method to some other method. We recommend EUA authorized high sensitivity molecular test. That's really looking at you know, when the reference test is positive, how many times out of 100 is your test that you're developing positive? So, if it's positive, say, you know 90% of the time when the high sensitivity molecular test is positive, then your PPA or sensitivity would be 90%. Positive predictive value has to do with it's more of a population based measure. Yes, we do look at PPV for direct antigen tests, but that PPV can vary widely depending on the percent positivity in a given population. When a population has a very low incidence of active coronavirus infection, you know, a test like indirect antigen test that may have a specificity of 99%, would have quite a low PPV. I think I mentioned recently, that if the prevalence of SARS infection detectable with a direct antigen test is 0.2%. The test is 99% specific, the positive predictive value is 16%. So, you know, basically five out of six positive results are false positives. And that doesn't mean there's anything wrong with the test. It just means that in a low percent positive population, you're going to, even with a relatively high specific test, like 99% pretty high. Hard to go above that significantly within with a direct antigen test. You just want to confirm those results, I think with another test. So, we don't have typically a specific recommendation for PPV. We do have expectations for specificity and sensitivity or PPA and NPA. Negative percentage agreement and positive percent agreement. And we would for direct antigen test as for molecular tests in the home environment, when it's done by prescription, it's the same expectation as any other and viral detection method and that is what I like to see.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Positive predictive value (PPV) requirements, At-home diagnostic and screening testing, FDA test performance expectations
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Does the at-home test template on the FDA website specify an appropriate number of subjects for a usability study?
CLARIFIED ANSWER: The appropriate number of subjects for a usability study is outlined in the FDA's home test template available on their website. For precise details, consult the template or email the FDA's template address for clarification.
VERBATIM QUESTION: Does the at-home test template on the FDA website specify an appropriate number of subjects for a usability study?
VERBATIM ANSWER: Yes, it that is that is in the home, I believe that's in the home test template that's on our website. And I don't remember I want to be accurate. Toby, unless you know, specifically, what that number is. I would just refer you to that. And then if you have any follow up questions, if the templates not clear, just send us an email to the templates, email address.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability study requirements, FDA home test template
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: What is the FDA's definition of surveillance testing as distinct from home use screening and diagnosis?
CLARIFIED ANSWER: Surveillance testing involves population-level assessments of the virus's presence or absence in a targeted population without providing CLIA results.
VERBATIM QUESTION: What is the FDA's definition of surveillance testing as distinct from home use screening and diagnosis?
VERBATIM ANSWER: Surveillance being that you're not really providing a CLIA result. You're doing population assessment of the presence or absence and at what level of the virus in it, in a targeted population basis.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA surveillance testing definition, Screening vs diagnosis, CLIA results
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: When conducting a usability study for a home test, how can developers clarify unclear information found in the FDA's templates?
CLARIFIED ANSWER: Developers can refer to the home test template on the FDA website for guidance. If anything is unclear in the template, they can email the templates email address for clarification.
VERBATIM QUESTION: When conducting a usability study for a home test, how can developers clarify unclear information found in the FDA's templates?
VERBATIM ANSWER: Yes, it that is that is in the home, I believe that's in the home test template that's on our website. And I don't remember I want to be accurate. Toby, unless you know, specifically, what that number is. I would just refer you to that. And then if you have any follow up questions, if the templates not clear, just send us an email to the templates, email address.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability study for home tests, FDA templates clarification
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: What are the FDA's expectations for sensitivity and specificity of at-home antigen tests used in a serial testing scenario?
CLARIFIED ANSWER: The FDA expects direct antigen tests to achieve at least 80% sensitivity (PPA) for single use. For serial testing with a two-pack, sequential tests may have a combined sensitivity that reaches the 80% threshold, even if individual tests are lower (e.g., 70%).
VERBATIM QUESTION: What are the FDA's expectations for sensitivity and specificity of at-home antigen tests used in a serial testing scenario?
VERBATIM ANSWER: We do have expectations for specificity and sensitivity or PPA and NPA. Negative percentage agreement and positive percent agreement. And we would for direct antigen test as for molecular tests in the home environment, when it's done by prescription, it's the same expectation as any other and viral detection method and that is what I like to see. For single use, we'd like to see 80% PPA or sensitivity or greater. We are open, as we've stated, as Jeff and I stated in our recent op ed in the hill, we are open to a lower single test PPA. You know, we mentioned 70%. If some sort of serial testing, a two- pack, perhaps have the test done on consecutive days or in days 1 days 3, is able to in a combined sense, get us to that 80% mark, we may indeed find that acceptable.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity and specificity, At-home antigen tests, Serial testing expectations
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: How does population positivity rate affect the positive predictive value (PPV) of direct antigen tests?
CLARIFIED ANSWER: The population positivity rate significantly impacts the PPV of direct antigen tests. In low-incidence populations, even a test with 99% specificity may yield a low PPV, such as 16% at 0.2% prevalence, meaning most positive results could be false positives. Additional confirmatory testing is recommended in such cases.
VERBATIM QUESTION: How does population positivity rate affect the positive predictive value (PPV) of direct antigen tests?
VERBATIM ANSWER: Positive predictive value has to do with it's more of a population based measure. Yes, we do look at PPV for direct antigen tests, but that PPV can vary widely depending on the percent positivity in a given population. When a population has a very low incidence of active coronavirus infection, you know, a test like indirect antigen test that may have a specificity of 99%, would have quite a low PPV. I think I mentioned recently, that if the prevalence of SARS infection detectable with a direct antigen test is 0.2%. The test is 99% specific, the positive predictive value is 16%. So, you know, basically five out of six positive results are false positives. And that doesn't mean there's anything wrong with the test. It just means that in a low percent positive population, you're going to, even with a relatively high specific test, like 99% pretty high. Hard to go above that significantly within with a direct antigen test. You just want to confirm those results, I think with another test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PPV of antigen tests, Population positivity rate, Testing accuracy
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: What additional confirmatory steps does the FDA recommend when a test has a low positive predictive value in populations with low virus prevalence?
CLARIFIED ANSWER: The FDA recommends confirming results from tests with low PPV (especially in low prevalence populations) by conducting another test.
VERBATIM QUESTION: What additional confirmatory steps does the FDA recommend when a test has a low positive predictive value in populations with low virus prevalence?
VERBATIM ANSWER: When a population has a very low incidence of active coronavirus infection, you know, a test like indirect antigen test that may have a specificity of 99%, would have quite a low PPV. I think I mentioned recently, that if the prevalence of SARS infection detectable with a direct antigen test is 0.2%. The test is 99% specific, the positive predictive value is 16%. So, you know, basically five out of six positive results are false positives. And that doesn't mean there's anything wrong with the test. It just means that in a low percent positive population, you're going to, even with a relatively high specific test, like 99% pretty high. Hard to go above that significantly within with a direct antigen test. You just want to confirm those results, I think with another test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low positive predictive value, confirmatory testing, population virus prevalence
REVIEW FLAG: False

QA Block 11-11
CLARIFIED QUESTION: How should developers address scenarios where a single test sensitivity falls below 80%, but serial testing over consecutive days may achieve the target sensitivity?
CLARIFIED ANSWER: FDA is open to single test sensitivity as low as 70%, provided serial testing (e.g., on consecutive or alternate days) achieves a combined sensitivity of 80% or higher. This is particularly important for identifying individuals in the first 5-7 days of infection when viral loads are highest.
VERBATIM QUESTION: How should developers address scenarios where a single test sensitivity falls below 80%, but serial testing over consecutive days may achieve the target sensitivity?
VERBATIM ANSWER: For single use, we'd like to see 80% PPA or sensitivity or greater. We are open, as we've stated, as Jeff and I stated in our recent op ed in the hill, we are open to a lower single test PPA. You know, we mentioned 70%. If some sort of serial testing, a two- pack, perhaps have the test done on consecutive days or in days 1 days 3, is able to in a combined sense, get us to that 80% mark, we may indeed find that acceptable. And again, as I've stated on previous calls, at this forum, we're most interested in identifying patients in the first 5 to 7 days of infection, when they have the highest viral load. That is viral loads that we think might very likely, although it's hard to get at this, corresponds to their ability to infect others. And so, we want to make sure we identify those people and we have a test that's sensitive to detecting those.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sensitivity threshold, serial testing, infection identification
REVIEW FLAG: False

QA Block 11-12
CLARIFIED QUESTION: What are the reporting requirements, if any, for surveillance testing as defined by the FDA, and where can developers find clarifications from CMS or CLIA?
CLARIFIED ANSWER: The FDA does not review tests used for true surveillance purposes but recommends using EUA-authorized tests. Developers should check with CMS or CLIA for any possible reporting requirements.
VERBATIM QUESTION: What are the reporting requirements, if any, for surveillance testing as defined by the FDA, and where can developers find clarifications from CMS or CLIA?
VERBATIM ANSWER: For truly surveillance purposes as defined in our FAQ, and you can go there, for this pandemic, the FDA is not reviewing those. We do obviously recommend that in those situations an EUA authorized test be used, but it's not a requirement. And there are different, you can check with CMS and in CLIA, there are different reporting, you know, there I don't believe there's reporting requirements, but double check with them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Surveillance testing, Reporting requirements, CMS/CLIA clarifications
REVIEW FLAG: False

QA Block 11-13
CLARIFIED QUESTION: What specific sensitivity and specificity thresholds are acceptable for at-home molecular and antigen viral detection methods performed with a prescription?
CLARIFIED ANSWER: The FDA expects at least 80% sensitivity (PPA) for single-use at-home antigen or molecular tests prescribed for viral detection. However, a lower threshold of 70% may be acceptable if serial testing (e.g., two-pack, consecutive days) achieves 80% sensitivity overall.
VERBATIM QUESTION: What specific sensitivity and specificity thresholds are acceptable for at-home molecular and antigen viral detection methods performed with a prescription?
VERBATIM ANSWER: And we would for direct antigen test as for molecular tests in the home environment, when it's done by prescription, it's the same expectation as any other and viral detection method and that is what I like to see. For single use, we'd like to see 80% PPA or sensitivity or greater. We are open, as we've stated, as Jeff and I stated in our recent op ed in the hill, we are open to a lower single test PPA. You know, we mentioned 70%. If some sort of serial testing, a two- pack, perhaps have the test done on consecutive days or in days 1 days 3, is able to in a combined sense, get us to that 80% mark, we may indeed find that acceptable.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity thresholds, Specificity expectations, At-home diagnostic tests
REVIEW FLAG: False


#### 12. Temperature Validation for Point of Care Testing Robustness

QA Block 12-1
CLARIFIED QUESTION: Why is there a need for performing point of care testing at 40 degrees Celsius when the average temperature in some areas is not that extreme?
CLARIFIED ANSWER: The FDA recommends testing at 40C because point-of-care tests may be used in non-healthcare settings without air conditioning, such as pop-up tents. Alternatives can be proposed, and labeling adjustments might be applied based on test performance to ensure appropriate usage conditions are clear.
VERBATIM QUESTION: Yes. My question is pertaining to point of care testing. With regards to the six further components of robustness testing. And one of the elements requires the test to be performed at high temperature. I was just wondering about how you rationalize the need for doing the test at 40 degrees Celsius when the average temperature around here is not even that extreme conditions? And is it really required for us to do that type of a temperature stress test, for point of care testing?
VERBATIM ANSWER: So those are our recommendations. If you want to propose alternate, that's fine. We may put limitation, temperature limitations, in your instructions for use. But we are seeing that these kind of point of care tests sometimes are used and in non-healthcare settings now, that may not have air conditioning. And so, in sometimes they're pop up tents and things like that. So that's the reason for asking that kind of temperature variation. But again, you know, we can label around certain potential, we have the option, when everything else looks good to look at whether or not we alter the labeling for your product. And it might say if your test, for example, doesn't perform well, we might say must be performed in, in temperature controlled environment between these temperatures. But it's really working with you to figure out when your test performs well. So, you know, so we asked for these flex studies. And we want to see if there is any impact on your test performance. And then It doesn't necessarily mean if there's an impact that we wouldn't authorize your test. It's simply that we want to alert users, that certain variables may impact the performance of the test. So, I'll pause there in case you have any clarifying questions. Hopefully that was clear and justifies why we asked those important questions.
SPEAKER QUESTION: Han Son
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care testing, Temperature robustness testing, FDA recommendations
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What options are available if a point of care test does not perform well at higher temperatures?
CLARIFIED ANSWER: FDA states that if a point of care test does not perform well at higher temperatures, it might be labeled as requiring a temperature-controlled environment with specific parameters. The FDA also works with developers to address temperature performance issues to ensure appropriate labeling and mitigate impacts.
VERBATIM QUESTION: What options are available if a point of care test does not perform well at higher temperatures?
VERBATIM ANSWER: So those are our recommendations. If you want to propose alternate, that's fine. We may put limitation, temperature limitations, in your instructions for use. But we are seeing that these kind of point of care tests sometimes are used and in non-healthcare settings now, that may not have air conditioning. And so, in sometimes they're pop up tents and things like that. So that's the reason for asking that kind of temperature variation. But again, you know, we can label around certain potential, we have the option, when everything else looks good to look at whether or not we alter the labeling for your product. And it might say if your test, for example, doesn't perform well, we might say must be performed in, in temperature controlled environment between these temperatures. But it's really working with you to figure out when your test performs well. So, you know, so we asked for these flex studies. And we want to see if there is any impact on your test performance. And then It doesn't necessarily mean if there's an impact that we wouldn't authorize your test. It's simply that we want to alert users, that certain variables may impact the performance of the test.
SPEAKER QUESTION: Han Son
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point of care test temperature performance, Flex studies, Labeling requirements
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: How might labeling be adjusted if a specific test requires a temperature-controlled environment?
CLARIFIED ANSWER: Labeling may be adjusted to specify that a test must be performed in a temperature-controlled environment with defined temperature ranges if performance issues at certain temperatures are identified.
VERBATIM QUESTION: How might labeling be adjusted if a specific test requires a temperature-controlled environment?
VERBATIM ANSWER: But again, you know, we can label around certain potential, we have the option, when everything else looks good to look at whether or not we alter the labeling for your product. And it might say if your test, for example, doesn't perform well, we might say must be performed in, in temperature controlled environment between these temperatures. But it's really working with you to figure out when your test performs well.
SPEAKER QUESTION: Han Son
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Labeling adjustments, Temperature-controlled testing, Test performance
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: What is the purpose of flex studies in evaluating test performance under variable conditions?
CLARIFIED ANSWER: The FDA uses flex studies to determine if variable conditions impact test performance. These studies help alert users to any potential performance impacts under specific conditions, though an impact does not necessarily preclude authorization.
VERBATIM QUESTION: What is the purpose of flex studies in evaluating test performance under variable conditions?
VERBATIM ANSWER: So, you know, so we asked for these flex studies. And we want to see if there is any impact on your test performance. And then It doesn't necessarily mean if there's an impact that we wouldn't authorize your test. It's simply that we want to alert users, that certain variables may impact the performance of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Flex studies, Test performance, Variable conditions
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Are there scenarios where the FDA might authorize a test despite performance variability at certain temperatures?
CLARIFIED ANSWER: The FDA may still authorize a test even if performance is impacted at certain temperatures, but users will be informed about variables that could affect its effectiveness.
VERBATIM QUESTION: Are there scenarios where the FDA might authorize a test despite performance variability at certain temperatures?
VERBATIM ANSWER: And then It doesn't necessarily mean if there's an impact that we wouldn't authorize your test. It's simply that we want to alert users, that certain variables may impact the performance of the test.
SPEAKER QUESTION: Han Son
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test authorization, temperature variability, performance impact
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: What steps should developers take to propose alternative robustness testing conditions?
CLARIFIED ANSWER: FDA allows developers to propose alternative testing conditions. Label modifications may be made to ensure appropriate usage settings but would depend on the test's performance evaluation.
VERBATIM QUESTION: What steps should developers take to propose alternative robustness testing conditions?
VERBATIM ANSWER: So those are our recommendations. If you want to propose alternate, that's fine. We may put limitation, temperature limitations, in your instructions for use. But we are seeing that these kind of point of care tests sometimes are used and in non-healthcare settings now, that may not have air conditioning. And so, in sometimes they're pop up tents and things like that. So that's the reason for asking that kind of temperature variation. But again, you know, we can label around certain potential, we have the option, when everything else looks good to look at whether or not we alter the labeling for your product. And it might say if your test, for example, doesn't perform well, we might say must be performed in, in temperature controlled environment between these temperatures. But it's really working with you to figure out when your test performs well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Robustness testing, Alternative testing conditions, Labeling modifications
REVIEW FLAG: False

### removed qa blocks
QA Block 7-2
CLARIFIED QUESTION: What kind of discussion is required with the FDA to use a mid-turbinate swab for a home-use antigen test?
CLARIFIED ANSWER: The FDA is open to home mid-turbinate swab use but suggests ensuring child safety through stoppers. Tests should be validated against high-sensitivity, EUA-authorized tests either in a home or simulated environment. Specific discussions should be initiated through FDA's templates email address.
VERBATIM QUESTION: What kind of discussion is required with the FDA to use a mid-turbinate swab for a home-use antigen test?
VERBATIM ANSWER: Okay. Well, we are very open to a home mid -turbinate use. And I don't know that we've authorized a mid-turbinate, but we've certainly expressed that in multiple occasions. The only caveat to that is in the home environment, we want to look at whether children would be swapped or not with a mid- turbinate. And if so, there are stoppers or other devices that can be utilized with a mid-turbinate swab that makes it appropriate for kids and it can be removed for adults. So that's the only sort of caveat on mid-turbinate. It would be unlikely for a direct antigen test to be more sensitive than a molecular test in the home situation. So, we want to compare it to an authorized version of the test, an EUA test, and typically I think in our recommendations, we say a high sensitivity test. And that can be performed in a lot of different settings. We're open to entirely in the true truly home setting. But you can also do have the users come into a simulated home environment and do testing. And then obviously, after they've collected the sample for your home test and tested it, they can be swapped by a healthcare worker and then sent in for an EUA authorized test. So probably some of those details that you're talking about, you know, would best be worked out with one of our review staff. So, if something is again, an alternate sort of pathway, then in our recommendations for the template from the home test template, then I would reach out through our templates email address and asked those specific targeted questions.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home-use mid-turbinate swabs, FDA validation requirements, Safety and test authorization
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What devices or features can make mid-turbinate swabs suitable for children?
CLARIFIED ANSWER: For children using mid-turbinate swabs, devices such as stoppers can be incorporated to make them suitable, and these can be removed for adults.
VERBATIM QUESTION: What devices or features can make mid-turbinate swabs suitable for children?
VERBATIM ANSWER: The only caveat to that is in the home environment, we want to look at whether children would be swapped or not with a mid-turbinate. And if so, there are stoppers or other devices that can be utilized with a mid-turbinate swab that makes it appropriate for kids and it can be removed for adults.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mid-turbinate swabs, pediatric suitability, diagnostic devices
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Will the standards from WHO and CDC for quantitative antibody assays be aligned?
CLARIFIED ANSWER: FDA does not currently have a definitive answer on whether WHO and CDC standards for quantitative antibody assays will align, but it is engaged with WHO and open to considering international standards.
VERBATIM QUESTION: Will the standards from WHO and CDC for quantitative antibody assays be aligned?
VERBATIM ANSWER: You know, that's a question I don't know the answer to right off the top of my head. We are open to any - to considering any international standard. We're obviously working with the WHO. Toby, are you aware specifically is the CDC doing something separate? Because I know that in all likelihood there are multiple parties within us government involved in the WHO standard development, not just for serology, but for antigen and molecular tests as well.
SPEAKER QUESTION: Elliot Cowan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: WHO and CDC standards, Quantitative antibody assays, FDA collaboration
REVIEW FLAG: True

QA Block 11-2
CLARIFIED QUESTION: What is an appropriate number of subjects for a usability study for an at-home test?
CLARIFIED ANSWER: The FDA suggests referring to the home test template on their website for guidance on the number of subjects for a usability study. If unclear, follow up via email.
VERBATIM QUESTION: What is an appropriate number of subjects for a usability study for an at-home test?
VERBATIM ANSWER: Yes, it that is that is in the home, I believe that's in the home test template that's on our website. And I don't remember I want to be accurate. Toby, unless you know, specifically, what that number is. I would just refer you to that. And then if you have any follow up questions, if the templates not clear, just send us an email to the templates, email address.
SPEAKER QUESTION: Daniel Roth
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability study, at-home tests, FDA guidance
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Is it required to perform a temperature stress test for point of care testing at 40 degrees Celsius?
CLARIFIED ANSWER: FDA recommends temperature stress testing at 40C due to the potential use of point-of-care tests in non-healthcare settings without air conditioning. Alternatives can be proposed, and FDA may adjust product labeling based on performance data.
VERBATIM QUESTION: Is it required to perform a temperature stress test for point of care testing at 40 degrees Celsius?
VERBATIM ANSWER: So those are our recommendations. If you want to propose alternate, that's fine. We may put limitation, temperature limitations, in your instructions for use. But we are seeing that these kind of point of care tests sometimes are used and in non-healthcare settings now, that may not have air conditioning. And so, in sometimes they're pop up tents and things like that. So that's the reason for asking that kind of temperature variation. But again, you know, we can label around certain potential, we have the option, when everything else looks good to look at whether or not we alter the labeling for your product. And it might say if your test, for example, doesn't perform well, we might say must be performed in, in temperature controlled environment between these temperatures. But it's really working with you to figure out when your test performs well. So, you know, so we asked for these flex studies. And we want to see if there is any impact on your test performance. And then It doesn't necessarily mean if there's an impact that we wouldn't authorize your test. It's simply that we want to alert users, that certain variables may impact the performance of the test. So, I'll pause there in case you have any clarifying questions. Hopefully that was clear and justifies why we asked those important questions.
SPEAKER QUESTION: Han Son
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: temperature stress testing, point of care testing, FDA labeling recommendations
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 07:24:57 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 12
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What steps should developers take if a pre-EUA question is closed by the FDA with a reference to existing templates?
QI 1-2: Under what circumstances should developers request feedback on alternative validation strategies?
QI 1-3: For validation strategies not covered in existing templates, how should developers seek further guidance from the FDA?
QI 1-4: What are the expectations for kit manufacturers submitting pooling submissions to minimize lab bench work?
QI 1-5: What criteria does the FDA use to prioritize the review of applications, particularly for pooling, point-of-care, and home testing?
QI 1-6: How should developers align their alternative validation approaches with the FDA before starting their work?

#### Section 2 of 12
##### Explicit Questions Extraction
QE 2-1: Can we secure the capability for pooling only for high and medium complexity contexts, but not for point of care?
QE 2-2: Does the FDA have any hesitation in approving pooling for a product only for the CLIA context, but not at the point of care for that product?
QE 2-3: Does the FDA require blanket testing to demonstrate pooling acceptability in all three contexts: high complexity, moderate complexity, and waived status?
QE 2-4: If we wanted to pursue point of care pooling, would human factors data be required to demonstrate healthcare workers can follow the pooling scheme?
QE 2-5: Are two separate studies required: a human factors study and a clinical study, or can a single clinical study examining user interaction suffice?

##### Implicit Questions Extraction
QI 2-1: What usability requirements need to be satisfied for pooling in a point-of-care setting?
QI 2-2: What are the validation expectations to ensure healthcare workers at the point of care can accurately perform pooling without training?
QI 2-3: Is the FDA open to approving pooling schemes specifically tailored to point-of-care settings if additional usability criteria are met?
QI 2-4: How does the FDA expect untrained healthcare workers to manage the pooling and deconvolution process to ensure result accuracy?

#### Section 3 of 12
##### Explicit Questions Extraction
QE 3-1: What has been the minimum average review time for authorization of a diagnostic PCR assay?

##### Implicit Questions Extraction
QI 3-1: What steps can developers take to ensure their EUA submission prioritization?
QI 3-2: How can developers pre-check with the FDA before pursuing alternative testing pathways?
QI 3-3: What constitutes a mismatch between FDA recommendations and a developer's test performance expectations?
QI 3-4: What happens if the data submitted with an EUA application is incomplete or insufficient?
QI 3-5: What are the FDA's expectations for the evidence supporting test performance?
QI 3-6: How can developers minimize delays during the interactive review process?

#### Section 4 of 12
##### Explicit Questions Extraction
QE 4-1: If new studies not indicated in the pre-EUA are needed, does updating the submission result in losing the place in the review queue?
QE 4-2: Is EUA review conducted on a rolling basis?
QE 4-3: What is the current turnaround time for antigen testing review?

##### Implicit Questions Extraction
QI 4-1: How are additional study recommendations communicated to developers when reviewers identify a need for them?
QI 4-2: What happens to an application while a developer conducts additional studies requested by a reviewer?
QI 4-3: Does the FDA consider study design clarity as part of the application review process?
QI 4-4: What factors in a study design might influence the FDA's review of a diagnostic application?
QI 4-5: How can applicants ensure their submissions are well-organized for faster review?

#### Section 5 of 12
##### Explicit Questions Extraction
QE 5-1: Could the substitution of a simpler liquid transfer mechanism take an assay from being a highly complex assay to a CLIA-waived point of care assay?
QE 5-2: What are the fundamental components of an assay that FDA would deem appropriate for point of care authorization that is not linked to an existing platform?
QE 5-3: What are the common features of these newly authorized point of care devices in terms of complexity assessment?
QE 5-4: What are the general criteria for assessing test complexity outside of a pandemic?

##### Implicit Questions Extraction
QI 5-1: What are the specific criteria for deeming a test as simple enough for CLIA-waived environments during the pandemic?
QI 5-2: How does the FDA evaluate pipetting steps in determining test complexity for CLIA-waived point-of-care tests?
QI 5-3: What studies are recommended for point-of-care authorization of new antigen tests?
QI 5-4: How does the FDA determine if workflows from previously authorized devices can be reused without additional studies?
QI 5-5: What considerations under the emergency use authorization differ from normal CLIA complexity classifications?
QI 5-6: What is the process for updating the molecular, antigen, and serology templates with new point-of-care studies during the pandemic?
QI 5-7: What level of detail is required in the instructions for use for a CLIA-waived setting test?

#### Section 6 of 12
##### Explicit Questions Extraction
QE 6-1: What are your thoughts on the potential value of serology testing in a post-vaccine world, particularly for characterizing individual immune response and monitoring antibody response over time?
QE 6-2: How might the demand for serology testing evolve in a post-vaccine world, potentially requiring millions to hundreds of millions of tests?
QE 6-3: Does data on antibody responses, including how they may vary by vaccine or ethnicity, affect the FDA's approach to evaluating serology tests?
QE 6-4: Are there plans to address claims about whether immune responses to vaccines are adequate or not in the context of serology testing?
QE 6-5: Is the FDA open to starting discussions with developers about serology testing related to vaccine responses?

##### Implicit Questions Extraction
QI 6-1: What criteria does the FDA use to rebalance resources between the molecular, antigen, and serology teams?
QI 6-2: Does the FDA anticipate adjusting its resource allocation further in response to shifts in testing demand?
QI 6-3: What is the process to seek FDA feedback on claims related to vaccine response adequacy?
QI 6-4: When making claims about vaccine responses, what additional data or documentation would the FDA require from developers?
QI 6-5: Will discussions about serology testing and vaccine response claims involve multiple FDA offices or Centers beyond just the OIR?

#### Section 7 of 12
##### Explicit Questions Extraction
QE 7-1: Is it allowable to use a mid-turbinate swab instead of a nasopharyngeal swab for a home-use antigen test with FDA discussion?
QE 7-2: What kind of discussion is required with the FDA to use a mid-turbinate swab for a home-use antigen test?
QE 7-3: Does the FDA require the use of only PCR tests that have been authorized for mid-turbinate sampling?

##### Implicit Questions Extraction
QI 7-1: Are mid-turbinate swabs appropriate for use in children for home tests, and are there specific requirements for their design?
QI 7-2: What devices or features can make mid-turbinate swabs suitable for children?
QI 7-3: Is it acceptable to compare a home antigen test to an EUA-authorized high sensitivity molecular test during validation?
QI 7-4: Can validation of a home antigen test be conducted in a simulated home environment instead of an actual home?
QI 7-5: What are the steps to follow in the validation process when using a healthcare worker to collect a follow-up sample after a home test?
QI 7-6: Is there a specific process for reaching out to FDA review staff to address alternate pathways not covered in the home test template guidelines?

#### Section 8 of 12
##### Explicit Questions Extraction
QE 8-1: Will the FDA have a preference between the CDC standards and the WHO standards for quantitative antibody assays?
QE 8-2: Will the standards from WHO and CDC for quantitative antibody assays be aligned?
QE 8-3: Is the CDC doing something separate from WHO in standard development for quantitative antibody assays?

##### Implicit Questions Extraction

#### Section 9 of 12
##### Explicit Questions Extraction
QE 9-1: Who should be contacted to request a reviewer be assigned for an EUA submission when no updates have been received for months?

##### Implicit Questions Extraction
QI 9-1: What is the expected timeline for assigning a new reviewer after an error in initial assignment?
QI 9-2: How frequently does the FDA recommend developers should expect updates on their submissions?
QI 9-3: Who should developers contact if there is uncertainty or prolonged delays in the EUA review process?
QI 9-4: Can developers escalate their issues directly to Dr. Stenzel or Toby Lowe in case of prolonged delays?
QI 9-5: Is there a specific protocol for addressing errors in reviewer assignment during the EUA process?

#### Section 10 of 12
##### Explicit Questions Extraction
QE 10-1: What is the benchmark for sensitivity and specificity for a LAMP assay being validated using the CDC PCR as a reference test?
QE 10-2: Do you have a marker for the limit of detection, such as 100 or 1000 virus copies?

##### Implicit Questions Extraction
QI 10-1: What is the FDA's minimum positive percent agreement (PPA) requirement for viral detection tests, including both antigen and molecular tests?
QI 10-2: Can viral detection tests with sensitivity below 95% still receive authorization if specific language or limitations are included in the labeling?
QI 10-3: Does the FDA require live or inactivated virus for limit of detection (LOD) studies?
QI 10-4: What is the process for requesting the FDA reference panel for a locked-down device?
QI 10-5: Can developers request the FDA reference panel even if they have not yet submitted an Emergency Use Authorization (EUA) application?
QI 10-6: How does the FDA determine and post relative LOD results using the FDA reference panel?

#### Section 11 of 12
##### Explicit Questions Extraction
QE 11-1: What are the differences in positive predictive value between home use diagnostic kits and home use surveillance kits in a multipack format?
QE 11-2: What is an appropriate number of subjects for a usability study for an at-home test?
QE 11-3: Does surveillance mean something specific in this context, as distinct from screening and home use diagnosis?
QE 11-4: What are the FDA's recommendations for positive predictive value for individual tests and for overall multipack tests in the context of at-home use screening and diagnosis?
QE 11-5: Does the at-home test template on the FDA website specify an appropriate number of subjects for a usability study?

##### Implicit Questions Extraction
QI 11-1: What is the FDA's definition of surveillance testing as distinct from home use screening and diagnosis?
QI 11-2: When conducting a usability study for a home test, how can developers clarify unclear information found in the FDA's templates?
QI 11-3: What are the FDA's expectations for sensitivity and specificity of at-home antigen tests used in a serial testing scenario?
QI 11-4: How does population positivity rate affect the positive predictive value (PPV) of direct antigen tests?
QI 11-5: What additional confirmatory steps does the FDA recommend when a test has a low positive predictive value in populations with low virus prevalence?
QI 11-6: How should developers address scenarios where a single test sensitivity falls below 80%, but serial testing over consecutive days may achieve the target sensitivity?
QI 11-7: What are the reporting requirements, if any, for surveillance testing as defined by the FDA, and where can developers find clarifications from CMS or CLIA?
QI 11-8: What specific sensitivity and specificity thresholds are acceptable for at-home molecular and antigen viral detection methods performed with a prescription?

#### Section 12 of 12
##### Explicit Questions Extraction
QE 12-1: Why is there a need for performing point of care testing at 40 degrees Celsius when the average temperature in some areas is not that extreme?
QE 12-2: Is it required to perform a temperature stress test for point of care testing at 40 degrees Celsius?

##### Implicit Questions Extraction
QI 12-1: What options are available if a point of care test does not perform well at higher temperatures?
QI 12-2: How might labeling be adjusted if a specific test requires a temperature-controlled environment?
QI 12-3: What is the purpose of flex studies in evaluating test performance under variable conditions?
QI 12-4: Are there scenarios where the FDA might authorize a test despite performance variability at certain temperatures?
QI 12-5: What steps should developers take to propose alternative robustness testing conditions?
